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ABSTRACT 
 
Background 
As antiretroviral medicines have become increasingly available and affordable for the treatment 
of HIV infected patients in South Africa, the adoption of a fixed dose combination (FDC) was 
implemented in 2013 as a strategy to improve adherence and to ensure that the emergence of 
resistant strains is delayed. Previous studies in other countries have shown that even with FDC, 
adherence was still below optimal levels. This study aimed to evaluate the impact of introducing 
the FDC regimen (emtricitabine/ efavirenz/ tenofovir) on adherence, virologic response, 
immunological response, retention to care and death rates compared to multiple dose regimens 
(MDC). 
Methods 
An institution based, adult patient retrospective record review was conducted at four facilities 
rendering ART services at Uthukela District, Kwa-Zulu Natal, for ART naïve patients from 
January 2013 to December 2013. A total of 800 records were sampled, 400 from each of 
Tenofovir/emtricitabine/efavirenz FDC and the MDC regimens. Proportion of days covered 
(PDC) and absolute adherence ( PDC≥ 95%) were used as parameters to determine adherence for 
each of the ART regimens, calculated from pharmacy records over a period of 84 days at 6, 12 
and 24 months after initiating treatment . Comparison of viral load (VL) suppression, mean Cd4 
count, retention to care and death rates as clinical outcomes ,was done for each group to determine 
regimen effectiveness. 
Results 
At 0-6 months, 85 patients switched from MDC to FDC, at 12 months 220 had switched, and at 
24 months 252 had switched (MDC unswitched). Mean PDC at 6, 12 and 24 months for FDC was 
(66± 30.29; 60± 34.27 and 54± 36.98days), for the MDC-switched Group was (74±20.14; 70± 
27.58 and 65± 33.59 days out of 84 days); and for MDC-unswitched was (59±36.85; 34±39.96 
and 22±36.99 days), the difference between FDC and MDC-switched was significant, p value< 
0.05, and significant between FDC and MDC-unswitched, p value < 0.05. Absolute adherence for 
FDC was (65,6%, 59.05% and 50.9%), MDC-switched (73.8%, 72.9% and 71.1%) and MDC-
unswitched (64.% 36.4% and 23.3%), at 6, 12 and 24 months. Females on FDC had higher PDC 
and Absolute adherence than males at 12 and 24 months.  VL suppression for FDC was [97%(249 
out of 256 tests), 86.2%(145/167), 89.3%( 191/124)], for MDC-unswitched [ 81.8% (23/27), 
82%(89/102) ,56%(153/181], p value<0.05, and  for MDC-switched [85.5% (23/27); 87.3% 
(89/102) , 84.5% (153/181)], p value>0.05 compared to FDC, at 6, 12 and 24 months respectively. 
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Patients on FDC, with PDC below 50%, had VL suppression rates above 90% at 6 months, but 
this could not be sustainable beyond 6 months. On  FDC, VL suppression for females was (97%, 
78.8% and 80%) versus males (89.16%, 87.18% and 83.05%),  the difference was only significant 
at 6 months, p value <0.05 At 24 months mean Cd4 count for FDC recovered by 152% from 
baseline, and by 126% for MDC unswitched.  Retention to care for FDC was [91.8% (368/400), 
91.8% (367/400), 91% (363/4000], for MDC switched [98.8%(84/85), 94.5% (208/220) and 
92.5% (233/252)], and for MDC switched [88.6%984/85), 95.5%9208/220), 81% (120/148) ] at 
6, 12 and 24 months respectively, p value <0.05. At 24 months the death rate for FDC was 4.75% 
(19/400), that of MDC switched 1.59% (2/252), and MDC unswitched 17.57% (26/148), p value 
< 0.05 compared to FDC. 
Conclusion 
The FDC regimen demonstrated better PDC and absolute adherence than the MDC regimen, 
however the group that switched from MDC to FDC demonstrated superior PDC and absolute 
adherence than FDC. Absolute adherence rates for all three regimen groups were less than the 
optimal level of 90%. VL suppression and Cd4 recovery were significantly higher for FDC than 
the MDC unswitched regimen. Even though females demonstrated higher adherence than males 
on FDC, there was no significant difference in VL suppression between the two genders. FDC 
demonstrated retention to care than the MDC regimen group. The implementation of the FDC 
regimen improved adherence and clinical outcomes for adult patients on ART. 
Keywords: Adherence, Fixed Dose Combination, Viral Load suppression, Retention to Care, 
Death rates,  Fixed Dose Combination ART 
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CHAPTER 1: INTRODUCTION 
 
1.1 Background 
As antiretroviral medicines become increasingly available and affordable for the treatment of 
human immunodeficiency virus (HIV) infected patients in South Africa, adoption of strategies to 
ensure that emergence of resistant strains of the virus are delayed, remains critical. These 
strategies have to be adopted to ensure that patients adhere to treatment to optimize the durability 
of present treatment regimens and to prolong life. 
The South African Department of Health in 2012, implemented the use Fixed Dose Combination 
antiretroviral regimen to improve adherence to treatment, minimize unnecessary drug toxicities 
for improved clinical outcomes (Khopotso, 2012), to retain patients on life-long therapy, prevent 
HIV Disease progression and avert Aids related deaths. Fixed-dose combinations (FDC) of ARV 
drugs are widely being promoted as a first-line regimen in treatment access programs. Additional 
advantages of using FDCs are reduced pill load, reduction in prescription errors, and easier 
delivery of treatments. 
A study done in Colorado, USA (Langness, et al., 2015) found that the proportion of days covered 
on a single regimen of PLWH taken once-daily was significantly higher than the proportion of 
days covered for multi-tablet once-daily regimens or multi-tablet twice-daily regimens. Research 
in India has shown that a fixed dose combination of generic Tenofovir/Emtricitabine/Efavirenz is 
effective, able to achieve viral suppression of 96% at 6 months for antiretroviral –naïve and 
experienced patients, and is safe to use in those with co-morbid conditions (Pujari et al, 2008). A 
study by Sax e al, 2012, in USA, observed that only 47% of patients achieved a 95% adherence 
when taking one pill a day. Another study done in the USA showed that non-adherence to Atripla, 
a fixed dose anti-retroviral combination, similar in composition to one used in South Africa, was 
as high as 30% (Clay, 2014). The Adherence Curve Theory assumes that at the start of therapy 
patients become motivated to adhere to their treatment, and often times this is supported by strong 
patient-provider relationship that is often demonstrated at the start of therapy. This motivation 
plateaus around 21 weeks after which this motivation declines with time as the patient gets better, 
and the support provided by clinicians also declines (Friedland, 1999).  
Contributing factors to low levels of adherence to antiretroviral therapy (ART) in South Africa, 
include patient related cultural practices including use of traditional medicines, which can be high 
as 36% (Peltzer, 2008), resulting in increased rate to drop- outs on treatment, increased drug-drug 
  
2 
 
 
interactions with ARV’s (Muller, 2011), viral resistance and treatment failure (Mills et al, 2005), 
however use of traditional medicines seems to decline with longer time of ART (Peltzer, 2008). 
Other challenges linked to low adherence are related to socio-economic status; socio-cultural 
environment of the patient, and location of public facilities where patients have to travel for long 
distances to get the intended care. A study conducted in Kwa- Zulu Natal showed that the distance 
between the health facility and the patients home have a significant contribution to non- 
adherence, compounded by socio-economic factors that impact on affordability to access 
transport to visit the clinics( Marconi, 2014). 
Long waiting hours and queues before patients can be able to seen by a clinician is a significant 
challenge in the public sector facilities.  Findings of a study done at kwaThema in SA (Melaku A 
et al, 2016), before the use of FDC, showed that self-report adherence assessments of patients on 
ART indicated that 82.8% adhered to treatment while 17.2% did not. Females had an adherence 
of 80.2% compared to that of males which was 69.9%.  
A study done in five sites in Johannesburg, south Africa, demonstated that in anti-retroviral 
therapy (ART) naïve patients that were enrolled between 2000-2010, retention in care was 60%, 
and mortality was 9%; and that  incomplete adherence amongst patients on HAART is linked to 
greater risk for residual low levels viremia (Keith, 2014). In a retrospective analysis study, rates 
of drug resistance were found to be lower with a fixed dose combination single tablet anti-
retroviral regimen, than with the same drugs taken individually (Bianco et al, 2014).   
Rationale for the study 
Since the introduction of HAART in the Public sector in South Africa in 2004, only multiple dose 
regimens have been used, initially based on Stavudine as the main Nucleotide Reverse 
Transcriptase of choice, and was often changed with Zidovudine (NDOH Anti-retroviral 
Guidelines, 2004). The implementation of the tenofovir/ emtricitabine/ efavirenz  FDC regimens 
was done through a phased-in approach, initially prioritising pregnant mothers, and those initiated 
on ART for the first time. This was then followed by those patients with co-morbidities including 
TB, and later those that were unstable to Stavudine or Zidovudine based regimens and needed 
switching to Tenofovir based regimens. Some of the clinicians were very reluctant to switch 
patients considered stable on multiple dose regimens to the fixed dose combination and switching 
took almost 18 months after the implementation of the guidelines. 
At Uthukela District the Lost to follow up rate to first line multiple dose regimens in 2012, prior 
to implementation of the FDC regimen was as high as 17% on average, ranging between 8% and 
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28 % at different facilities (Uthukela District health plan, 2013). Following a report from National 
Core standard assessments at Uthukela District, in March 2014, non-adherence to anti-retroviral 
treatment in the district of Uthukela was still high, with adherence levels of 68%.  
This study was conducted to ascertain whether there were differences in adherence to treatment, 
in virologic, immunologic response, retention to care and death rates as clinical outcomes between 
patients on Fixed Dose Combination (FDC) anti-retroviral drugs, and those that remained on 
multiple dose regimens in the public sector in Uthukela Health District, South Africa. 
1.2 Literature Review 
1.2.1 Adherence to Anti-retroviral treatment 
Medication adherence is defined as the extent to which a patient takes prescribed medication 
according to the dosage and frequency recommended by the provide (Andrade, 2006). 
The number of daily doses taken affects adherence to anti-retroviral treatment (Grierson et al, 
2011). Various factors contribute to non- adherence to highly active Anti-Retroviral therapy 
(HAART). These are Chronicity, complexity of the treatment regimen, tolerance to treatment, 
concomitant use of other medication, socio-emotional and biological development of the patient, 
and the health care system (Grierson et al., 2011). 
Improving access to virologic monitoring in Resource restrained settings is essential to 
maximizing HIV treatment outcomes (Hicks, 2013) 
1.2.1.1 Factors contributing to non-adherence to HAART 
Chronicity of regimens 
Nowadays HIV infection is no longer a death sentence, but rather a chronic disease. Patients 
remain on treatment for a lifetime. However, it has been shown that that after 6 months of 
treatment adherence generally declines (van Dulmen, 2007). A study by DiMatteo indicated that 
on average 24.8% of patients on HAART will be non -adherent to treatment and that this rate 
increases even further to 58% amongst patients with co-presentation of psychiatric disorders and 
depression (DiMatteo, 2000).  
Complexity of regimens  
Research on treatment adherence among most patients with chronic diseases suggests that 
increased complexity of medication regimens is associated with decreased adherence.  Regimen 
complexity refers to the number of doses taken per day, the number of pills per dose, the number 
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of different medications taken, and the presence of any food-dosing restrictions or requirements 
(Mayer, 2001). 
HAART regimens can, at times, be extremely complex, involving many doses, many pills, and, 
often, one or more medications taken for other co-morbid conditions. The complexity of HAART 
regimens sometimes requires patients to alter their eating and sleeping patterns and requires them 
to change their daily routine. In a Gardel study done in Europe a two drug regimen performed 
better than a three drug ART regimen in terms of side effects (Cahn et al, 2014). On the African 
Continent, a study done in Zimbabwe found that only an estimated 34% of patients were able to 
access care due to long distances to clinics (Campbell et al, 2012). However, some studies done 
in Sub-Saharan African countries have found that even in poor resource settings, levels of 
adherence to ART treatment can be higher than the privileged North American countries 
(Vreeman et al, 2008), and this can be attributed to supportive networks and a stronger sense of 
collective responsibility that still exists in the African culture (Ware et al, 2009). Earlier studies 
have always indicated that increased complexity of a treatment regimen is likely to increase 
likehood of adherence problems and that treatment regimens of more than one medication are 
associated with lower adherence rates (Deeks et al., 2010). Prescriptions of multiple medications 
on different medication schedules also have likelihood for non-adherence (Cahn, 2014). 
Taking a single tablet in fixed dose combination, reduces the pill burden taken by the patients; 
simplifies prescribing,  dispensing and stock management since the patients takes only one tablet 
instead of many more in multiple dose regimens ( Davies, 2013).  
Tolerance to treatment 
Regimens that produce immediate negative physical side effects have been proven to be difficult 
to adhere to. Anti-retroviral are often associated with immediate side effects, for an example 
Immune Reconstitution Syndrome, Hypersensitivity reactions, Gastro-intestinal disorders, and 
general body malaise, to name a few, quite early on initiation of treatment, and this usually , if 
not communicated well to the patients, is often a deterrent to further use of medication (Martin et 
al, 2005) . 
Concomitant use of other medication, including traditional medicines 
The use of traditional and complementary medicines in South Africa has been linked to low levels 
of adherence to HAART. In KwaZulu- Natal, herbal medicines used by HIV infected patients 
mainly for pain relief, immune boosters, and for stopping diarrhea, were associated with reduced 
ARV adherence (Peltzer et al, 2008). In a Pretoria setting, patients who use non prescribed 
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medicines, including over the counter and herbal medicines have a self-reported adherence level 
of less than ideal 95% (Malangu, 2007). 
Taking concomitant traditional medication with HAART may have  clinically significant 
pharmacokinetic drug interactions mostly with protease inhibitors, and Non Nucleotide Reverse 
Transcriptase Inhibitors ( NNRT’s)  of which Efavirenz one is of;  some of the traditional 
medicines concerned  were  St. John Wort, Garlic, Cats claw, and African traditional medicinal 
plants and extracts, such as, Hypoxis hemerocallidea, Sutherandia frutescens, Cyphostemme 
hildebrandtii, Acacia nilotica, Agauria salicifolia and elaeodendron buchananii (Muller et al, 
2011).  
Social, Emotional and Biological Development of HIV Infected patients 
In general, demographics such as age, gender, religion and educational level, have not been 
consistent predictors of adherence. However age in children can be quite significant inaffecting 
adherence, especially in adolescents. Adolescents have a tendency to neglect their medical care 
to avoid appearing different from their peers. Adolescents are often pre-disposed to higher stress 
as they might struggle with coping skills with some challenges they will be facing socially. 
Puberty, as well as some of the ART side effects,  are often associated with changes in distribution 
of fat and muscle mass, which might result in the adolescents having  poor self- esteem about 
themselves causing them to be more stressed, increasing their chances for non- adherence to 
treatment (Thompson, 2012). 
Alcohol Use and use of hazardous substance and drug abuse 
A study done recently in South Africa showed that 37% of 1503 patients attending clinics 
indicated hazardous/ harmful drinking, and 13% indicated having problems with drug abuse; this 
was linked to poor clinical outcomes and lower Cd4 counts ( Kader and Seedat, 2014). Active 
alcohol and or substance abuse have been identified as predictors of poor adherence (Behrens, 
2010). 
Access to medication and long waiting times 
The health care system has a direct effect on how the patient participates and co-operates with 
their medical treatment. Primary care provider turnover was associated with bad patient 
experience, reduced quality and increased mortality (Reddy et al., 2015).   
The ease to readily access medication for treatment has a significant impact on adherence. Shorter 
clinic waiting time contributes to willingness to attend appointment visits, especially for patients 
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that are working, and are not able to wait for long periods to pick up their medication. Very often 
patients have to take a full day off work to attend clinics due to long waiting times, which further 
impacts on their productivity at work, and compromised finances (Komu, 2008)  
A recent study conducted in Kwa- Zulu Natal showed that the distance between the health facility 
and the patients home have a significant contribution to non- adherence, compounded by socio-
economic factors that impact on affordability to access transport to visit the clinics( Marconi, 
2014). 
Health care provider- Patient relationship 
Adherence is related to the quality, duration and frequency of interaction between the clinician 
and the patient. The clinicians friendliness and approachability enhance patient’s perception that 
they are important and cared for, and this improves communication, where the patient is able to 
verbalize challenges that they might have with adherence, and the techniques they can adopt to 
improve adherence. Management through partnership with patients and other health care 
providers were reported as factors contributing to improve adherence (Naidoo, 2011). 
Communication of regimen requirements 
Educational strategies such as adherence classes or one- to- one counselling have a positive effect 
on adherence, however, communication without written information has been shown not to be 
very effective in improving adherence. A combination of educational and behavioral strategies 
with written information, to aide patient recall is recommended (Vermeer et al, 2008). 
Staff shortage and Patient support systems 
Patient-to staff ratio has been shown to be a factor impacting on patient adherence (Schneider H 
et al, 2010). Collaboration between the different health care professionals; doctors, pharmacists, 
nurses, social workers, dieticians, and other health care workers, to provide patient adherence 
support enhances better patient care and understanding of the complex factors that contribute to 
patient non-adherence (Naidoo, 2011). 
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Drug availability 
Medication possession ratio and medication availability have been factors shown to affect and to 
assess adherence in several pharmaco-epidemiological and pharmacoeconomic studies (Andrade 
et al, 2006).  
1.2.2. Strategies to Enhance Adherence to HAART 
Some of the strategies adopted to enhance adherence are to simplify the regimen as much as 
possible while incorporating the necessary potency Stone, 2001). Stone argues that when HAART 
regimen is individualised according to the patient’s lifestyle, the recommended dosage regimen 
is easier to adhere to. He suggests that attempts need to be made as far as possible to avoid 
medications known to commonly cause extremely unpleasant side effects. Proactively managing 
these side effects, and informing patients thereof minimises the risk of the patient to suddenly 
stop medication. The patients are then able to identify these side effects and would often approach 
health care for management. The use of pictograms and photographs of the medications can be 
very helpful in understanding directions for medication use. The use of pill calendars and pill 
boxes are useful tools that can be used as reminders. Programmed sms’s are now being used, with 
advancing technology, as almost 70% of the population use a telephone handset. (Stone, 2001) 
1.2.3 Safety and Effectiveness  
Efficacy and toxicity of Tenofivir/Emtricitabine and Efavirenz Fixed dose combination 
In treatment-experienced adults with HIV-1 infection already virologically suppressed with ART, 
switching to once-daily triple combination therapy with Efavirenz, Emtricitabine and Tenofovir 
(including the single-tablet regimen ATRIPLA),  was found to be effective in maintaining 
virological suppression and was generally well tolerated up to 96 weeks' duration (Deeks, 2010). 
In the  United States of America Atripla demonstrated advantage over single drugs with respect 
to lipid and haemolytic parameters and equivalent incidence of renal toxicity, but bone density 
seemed to decrease (Clay , 2008). 
Another study conducted in antiretroviral (ARV)-naive and experienced patients where thymidine 
analogue nucleoside reverse transcriptase inhibitor [tNRTI] was replaced by Tenofovir Diproxil 
Fumarate (TDF) in West India, in 2007; results showed that 96% of the patients were virologically 
suppressed after 6 months of initiation of treatment, but 2.8% of the TDF Fixed dose combination 
regimen reported grade 3-4 renal toxicity, higher than was expected (Pujari 2008). 
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Pozniak et al., in 2006, demonstrated that a multiple dose Tenofivir/ Emtricitabine and Efavirenz 
regimen, versus a Fixed dose combination of Zidovudine/ Lamivudine / Efavirenz, showed better 
therapeutic outcomes, at 48 weeks , with the multiple dose TDF regimen showing 75% viral 
suppression, versus the Fixed dose combination that was zidovudine based that showed 62% viral 
suppression. There was also a significant increase in Cd4 count, 270 vs 237 cells/mm3. This study 
indicates that taking a fixed dose combination does not necessarily result in improved clinical 
outcomes, and that the regimen make-up also contributes to clinical outcomes. 
However an open label non inferiority study conducted in 2006, by Gallant et al, indicated that a 
fixed dose combination of Tenofovir/Emtricitabine/ Efavirenz showed superior results in viral 
suppression versus a fixed daily dose of Zidovudine/ Lamivudine and Efavirenz (84% versus 73% 
respectively). Immunological function was also better with the TDF Fixed dose regimen, with 
increases in Cd4 count being 190 vs 158 cells/mm3. More patients in the Zidovudine/ Lamivudine 
group experienced adverse effects than the Tenofivir/ Emtricitabine group (9% vs 4%). This study 
confirmed the superiority of Fixed dose Tenofivir over a fixed dose Zidovudine regimen. 
Emtricitabine versus Lamivudine 
The chemical name of emtricitabine is 5-fluoro-1-(2R,5S)-[2(hydroxymethyl)-1,3-oxathiolan-5-
yl] cytosine. Emtricitabine is the (-) enantiomer of a thio analogue of cytidine, which differs from 
other cytidine analogs in that it has a fluorine in the 5-position. 
It has a molecular formula of C8H10FN3O3S and a molecular weight of 247.24. It has the following 
structural formula: (Gallant et al., 2006) 
 
Figure 1.1: Structural formula of Emtricitabine 
FTC (Emtricitabine) and 3TC (Lamivudine) are structurally very similar, FTC having just one 
additional fluorine molecule. In a recent technical update, the World Health Organization (WHO) 
concluded that 3TC and FTC are clinically and programmatically interchangeable.   
Although few direct comparisons have been performed, 3TC and FTC appear to have comparable 
virological and clinical efficacy and safety. 3TC may rarely be associated with pure red-cell 
  
9 
 
 
aplasia, which requires drug substitution, and FTC may occasionally cause palm discolouration, 
which is usually managed by reassuring patients. Both drugs are active against the hepatitis B 
virus. Therefore, WHO concludes that ‘FTC is an acceptable alternative to 3TC and that 3TC may 
substitute for FTC or vice versa. Both 3TC and FTC can be given as a single daily dose. 
1.2.4 Fixed Dose Combinations (FDCs) 
1.2.4.1 Formulation of the fixed dose Combination drug 
The Fixed dose combination formulation that was on SA government tender was based on 
generics manufactured by Aspen and  Cipla and each ach tablet contains 600 mg of efavirenz, 
200 mg of emtricitabine, and 300 mg of tenofovir DF (which is equivalent to 245 mg of tenofovir 
disoproxil) as active ingredients. The tablets included the following inactive ingredients: 
croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, 
and sodium lauryl sulfate. The tablets are film-coated with a coating material containing black 
iron oxide, polyethylene glycol, polyvinyl alcohol, red iron oxide, talc, and titanium. 
1.2.4.2 Advantages of Fixed Dose Drug Combinations  
Regimen and stock management simplification 
The use of FDC results in simplified ART prescribing, dispensing and stock management because 
the number of tablets is reduced when combined to a single tablet (Khapotso, 2013).   
Adherence 
By reducing the pill burden of the first-line regimen to one pill once daily may improve adherence 
levels. However, the provision of intensive adherence counselling remains essential (Deek, 2010).  
Efficacy  
Research has shown that a fixed dose combination of generic Tenofovir/Emtricitabine/Efavirenz 
is effective, able to achieve viral suppression of 96% at 6 months for ARV –naïve and experienced 
patients, and is safe to use in those with no co-morbid conditions (Pujari et al, 2008). Other studies 
showed an advantage of fixed dose combination over those regimens with more complex or 
frequently administered regimens (Deeks et al, 2010). 
 1.2.4.3 Disadvantages of Fixed Dose combinations 
Disadvantages of fixed drug combinations are often expensive, offer reduced flexibility in dosing, 
exposure of patients to drugs that they do not need and possibly increasing the risk of adverse side 
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effects, without increase in therapeutic benefit, and might results in incompatible 
pharmacokinetics of the individual drugs (Kaplan, 2004). 
1.2.5 Multiple Single-Dosage Regimens 
1.2.5.1. Definition of a multiple dosage regimen 
“Multiple dosage regimens are defined as the manner in which the drug is administered in suitable 
doses by suitable route, with sufficient frequency that ensures maintenance of plasma 
concentration within a therapeutic window for entire period of therapy” (Rowland et al, 2014). 
Multiple dosing regimens involve taking a number of dosing formulations throughout the day, 
and taking of individual drugs separately. 
1.2.5.2 Advantages of multiple dosage regimens 
Advantages of using multiple dose regimens assist in identification of the causal drug when 
patients experience side effects. Fixed dose combinations and once a day dosing regimens may 
result in higher peaks of drug concentration reached that might result in toxic doses reached and 
increased side effects and adverse reactions of the drugs. Giving doses in multiple dose tailored 
for the drugs half- life, may reduce chances of this happening. With multiple dosing a clinician is 
able to vary the dose of drug given and allows individualized patient management and flexibility. 
1.2.5.3 Disadvantages of multiple dosage regimens 
Multiple dose regimens result in higher pill burden for the patients as the patients has to take 
tablets more frequently and has to take more than one drug, which has implications on increased 
non-compliance to treatment. It is much more difficult to explain complex regimens to patients 
thus compromising correct dosing and pill identification.  
1.2.6. Theoretical Models 
Two models were applicable to the study on adherence to treatment. To assess adherence the 
Health Belief Model suggests that patients must be involved as partners in their care. The Health 
Systems Model assists determine some of the factors to be considered that could contribute to 
optimal clinical care of the patient. 
1.2.6.1 The Health Belief Model 
The health belief model was developed in the 1950s, and is described as a psychological health 
behavior change model to explain and predict health-related behaviors, particularly in regard to 
the uptake of health services (Hochbaun, Rosenstock and Kegels).This model remains one of the 
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most well-known and widely used theories in health behavior research. The health belief model 
suggests that people's beliefs about health problems, perceived benefits of action and barriers to 
action,and self-efficacy explain engagement (or lack of engagement) in health-promoting 
behavior. More recently, the model has been applied to understand patients' responses to 
symptoms of disease and compliance with medical regimens ( Glanz, 2002).  
Table 1.1: Health Belief Theory at a Glance (Glanz et al, 2002, p. 52) 
Concept  Definition 
Perceived Susceptibility One's opinion of chances of getting a condition 
Perceived Severity One's opinion of how serious a condition is and its consequences  
Perceived Benefits One's belief in the efficacy of the advised action to reduce risk or 
seriousness of impact 
Perceived Barriers One's opinion of the tangible and psychological costs of the 
advised action 
Cues to Action Strategies to activate "readiness" 
Self-Efficacy Confidence in one's ability to take action 
Although the health belief model attempts to predict health-related behaviors by accounting for 
individual differences in beliefs and attitudes, it has its limitations in that, it does not account for 
other factors that influence health behaviors. For instance, habitual health-related behaviors (e.g., 
smoking) may become relatively independent of conscious health-related decision making 
processes. Additionally, individuals engage in health-related behaviors for reasons unrelated to 
health (e.g., exercising for aesthetic reasons). Environmental factors outside an individual's 
control may prevent engagement in desired behaviors (Glanz, 2002). 
1.2.6.2. The Health Systems Model 
The Health Systems model seems to be appropriate for addressing some of the environmental 
factors that have impact on health relate behaviour and health outcomes. Kleiman’s Model of 
Health Care Systems states that patients and healers exist within a cultural construct, and explains 
how people in a particular social setting, think about, act in, and use a health care system 
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(Kleinman, 1980). He proposes that the health system has 3 components: the professional sector 
that uses methods and materials in healing people; the popular sector, and the Folk (family) sector. 
The popular sector is comprised of lay, non-specialist persons who depend on the opinions and 
evaluations of the professional sector. Within the populist sector, are individuals, families, 
communities, social network and community beliefs. The popular sectors major interest is health 
maintenance within the community, and community integrity. The model states that the family 
has influence on how the person seeking health care behaves.  Kleinman states that each sector 
creates its own clinical beliefs and norms associated with sickness, health care seeking behaviour, 
practitioner-patient relationships, therapeutic activities, and evaluation of outcomes (Kleinman 
1980). 
Elements of the Health Systems Model  
Reddy (2015) argues that, for Professional health system to be functional, Leadership and 
Governance, Delivery systems accessed by population, funding, drug availability, including 
widespread availability of anti-retrovirals, laboratory services and a trained workforce, the 
following elements are necessary for effective service delivery. 
Leadership and Governance within the context of the department of Health as stated in South 
Africa include, evidence based treatment guidelines, partnerships and co –ordination, health, 
system strengthening, district Health information strengthening, communication and improved 
referral systems, service delivery improvement, team work and change management for scaling 
up of services (Mullins, 2007). 
1.2.6.3 The Integrated Chronic Disease Management Model (ICDM) 
Integrated Chronic Disease Management can be defined as the provision of person-centered care 
in which health services work with each other and the client to ensure co-ordination, consistency, 
and continuity of care over time and through the different stages of their condition. This includes 
coordinated care using a team based, support for self-management approach, regular review and 
follow up of the patient (Department of Health ICDM Guidelines, 2014). 
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 1.3. Problem Statement and rationale for conducting the research study  
 
In April 2013, the Department of Health introduced a Fixed drug Combination pill, containing 
Tenofivir 300mg, Emtricitabine, and Efivarenz 600mg, with the purpose of improving cost to 
Anti-retroviral treatment (ART) and patient adherence to treatment (Davies, 2013) . The FDC 
regimen introduced was Tenofivir -based, with the one tablet only taken in the evening, while 
with earlier multi-dose regimens the drugs were taken as single drugs, often taken more 
frequently.  
The GS 99-934 study conducted in USA( Gallant et al, 2006) indicated that a drug combination 
of single elements of Tenofivir,  Emtricitabine and Efivarenz showed  superiority over Combivir  
(Zidovudine/ lamivudine) and Efavirenz combination with viral suppression ( 84% versus  73%)  
at 48 weeks, and 75% versus 67% at 96 weeks of therapy. In another study, the ACTG study, 18% 
of patients on Atripla had 185 Clinical Grade 3 and 4 adverse drug reactions, and 32% laboratory 
significant adverse effects. In both studies participants discontinued treatment due to intolerance 
and toxicity to the FDC ( Julg, 2008). 
 Although research has shown evidence of better adherence to fixed dose regimens, (Kling J, 
2014) in management of Chronic Obstructive Pulmonary Disease, and in hypertensive patients 
(Gupta et al, 2010), very few studies have been conducted in South Africa to measure adherence 
on fixed dose combinations (FDCs) compared to those on multiple dose regimens; and whether 
fixed dose regimens are safer and show better therapeutic outcomes than the multi-dose regimens. 
There is a need for monitoring of adherence for a treatment programme as it provides the health 
providers with an opportunity to identify non-adherence and structure constructive interventions 
to mitigate and to re-enforce adherence. Another reason why adherence is important in HAART 
is that even though the patient may show signs of being physically well, indicated by improving 
Cd4 counts, there is a chance that, if there is interruption in treatment, there could be ongoing 
viral replication because of mutant viruses that could emerge, which could be not as destructive 
as the wild type, but would still cause eventual decline in patient survival (Steele, 2007). Patients 
on multiple-dose regimens are often non- adherent to treatment, resulting in poor clinical 
outcomes indicated by clinical presentation of Opportunistic Infections, whist on treatment, and 
poor virological suppression (Ajose O, 2012). However a meta-analysis to compare adherence, 
safety and effectiveness of fixed dose combinations of anti-hypertensive agents to single drugs, 
found a significant improvement in adherence with no significant beneficial trends in Blood 
Pressure control and in adverse effects (Gupta et al, in 2010). 
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This study was conducted to ascertain whether there were differences in adherence to treatment, 
and in drug regimen effectiveness between patients on Fixed Dose combination Anti-retroviral 
drugs, and those on multiple dose regimens in the public sector in Uthukela Health District, South 
Africa. 
1.4. Research questions, hypothesis and objectives  
1.4.1. Research Questions 
The general question of this study was as follows: “Is the Fixed Dose combination anti-retroviral 
regimen having better adherence and effectiveness than multiple dose regimens in adult patients 
in public sector?” 
Our specific questions were as follows: 
 Will the fixed dose combination formulation and the resultant reduced pill load 
result in better adherence to ARV treatment than multiple dose regimens? 
 Will the difference in females and male adherence be bridged by the introduction 
of the fixed dose combination regimen when compared to multiple dose regimens? 
 Do patients on FDCs have better clinical outcomes than those on multiple dose 
antiretroviral regimens? 
1.4.2 Hypothesis 
The null hypothesis assumed that there would be a difference in adherence levels, immunologic 
and clinical outcomes between ARV patients on fixed dose Tenofivir/ Emtricitibine/ Efivarenz 
combination and those on multiple single-dose regimens. 
1.4.3 Aims and Objectives of this study 
1.4.3.1 Aim  
The aim of the study was to compare adherence to treatment and effectiveness in patients on Fixed 
Dose combination anti-retroviral drugs to those on multiple dose regimens in adult patients in 
public sector. 
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1.4.3.2 Objectives 
The specific objectives of this study were: 
1. To establish whether  the fixed dose combination formulation and the resultant reduced 
pill load result in better adherence to ARV treatment than multiple dose regimens. 
2.  To determine if gender was a significant factor in adherence on FDC compared to 
multiple dose regimens  
3. To determine the effect of FDCs on immunological response, viral load suppression and 
mean Cd4 count for FDC were compared to multiple dose antiretroviral regimens. 
4. To compare retention to care rates  between FDC and MDC ART regimens 
5. To compare death rates between FDC and MDC regimens 
 
1.5 Research Methodology 
1.5.1 Study Design   
An institution based, retrospective patient record review was conducted at four Health facilities 
of Uthukela District, Kwa-Zulu Natal, rendering ART services. 
1.5.2 Study area and Period 
The study was conducted from January 2016 to December 2017 at four health facilities that were 
rendering comprehensive ART services at Uthukela District, Kwa-Zulu Natal. 
1.5.3 Source and study population 
Patient record retrospective reviews of adult patients that were ART naïve on initiation of 
antiretroviral therapy, and presenting with no active opportunistic infections, were conducted. 
The study subjects were initiated on the 1st line treatment regimen according the South African 
ART Treatment guidelines (2013). The study subjects were randomly selected from 4 health 
facilities in the district, stratified to allow one facility from each level of care, to include: 1 
Regional hospital,1 district hospital, 1 Community Health Centre,  and 1 Primary health care 
facility ( randomly selected from the 4 local municipalities that make up the district. 
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1.5.4 Study subjects 
Study subjects were stratified according to the two groups:  
Group 1: Patients initiated on Fixed Dose Combination (FDC) ART regimen; of Tenofivir, 
Emtricitabine and Efivarenz, taken once a day. 
Group 2: Patients initiated on any other multiple- dose ART regimen. 
 1.5.4 1 Inclusion Criteria and Exclusion Criteria 
1.5.4.1.2 Inclusion Criteria 
Study subjects were Adult patients (above 18 years of age) who had been on 1st line ARV 
treatment. Only those patients who were ARV naïve on initiation of ART therapy were included 
in the study. 
1.5.4.1.2 Exclusion Criteria 
Patients younger than 18 years 
Patients not on antiretroviral therapy 
Patients presenting with any other known comorbid condition on initiation (for an example; TB, 
opportunistic infections, diabetes, and hypertension). 
Patients on 2nd line regimens   
Pregnant women that would have been exposed to the PMTCT programme before initiation on 
HAART. 
1.5.5 Sampling Procedure 
1.5.5.1 Sampling of Facilities 
Data was collected  from 4 health facilities in the district, one facility at each level of care, to 
include: 1 Regional hospital,1 district hospital, 1 Community Health Centre, and 1 Primary health 
care facility randomly selected from the 4 sub-districts  using stratified random selection from the 
4 local municipalities in the district. 
1.5.5.2 Sampling of subjects 
Using a formula by Naing et al, a minimum of 328 participants for each regimen group was 
required to detect at least 10% difference, a power of 80%, and 95% confidence interval. The 
sample size was estimated by using the formula: n = P (1-P) (Z-α/2/E), where P = total number 
of clients on treatment, (Z - α/2) = a constant code representing 95 % of confidence [1.96], E = 
margin of error [+/- 0.05] (Glenn, 1992). An assumption was made to detect at least 10 % (P = 
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10%) using the above formula. To accommodate for loss to follow up and drop outs 20% was 
added to the minimum sample size, a maximum of 400 participants per study group was used in 
this study. A total sample size of 400 patients on Fixed Dose regimen and 400 patients on multiple 
dose regimens were included in the final assumption of the sample size. A total Sample size of 
800 participants formed the cohort for the study. This maximum sample size was divided among 
the four facilities included in the study. 100 patients were randomly selected from each of the 4 
facilities for fixed dose combination and multiple dose regimens, respectively, using the formula 
(n+×)  based on total number of patients per type of regimen in each facility. For example for 
facility identified as PHC, with 341 patients on multiple dose, the formula n+3 was used for 
selecting 100 clinical chart records. 
1.5.5.3 Recruitment and selection of study Subjects 
Study subjects were patients who started ART therapy in January 2013 to December 2013. The 
subjects were selected from each of the 4 study facilities, and were stratified according to the 
ARV treatment regimen they have been initiated on. Study subjects should have been on 1st line 
ART regimen and should have been on treatment for a minimum period of 3 months, and were 
initially stratified into two groups as follows:. 
Group 1: Patients on Fixed Dose ARV combination of Tenofivir, Emtricitabine and Efivarenz, 
taken once a day. 
Group 2: Patients on multiple- dose, 1st line ART regimens. 
1.5.6 Data Collection technique and research instruments 
1.5.6.1 Data collection to establish differences in adherence between fixed dose combination 
and multiple dose regimen regimens 
Adherence to HAART can be measured by a variety of methods. The most commonly used 
methods are pill counts, review of pharmacy records and determination of days covered over a 
prescribed period, self-reporting, and use of such electronic medication-monitoring devices as 
MEMS.  
No single method has been established as the “gold standard” for measuring adherence. All 
methods have advantages as well as disadvantages. For example, MEMS are advantageous 
because of the detailed information they provide regarding the patient's pattern of taking 
medication, the percentage of doses taken, and the accuracy of the timing of doses, but this method 
is costly. 
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Proportion of days covered was used in this study as a Quasi objective measure of adherence to 
treatment,  calculated as a ratio of tablets that were in the patients possession compared to the 
actual number of tablets they should have had over a pre-determined period. For this study this 
was measured over an 84 day period, using pharmacy dispensing medication collection history. 
Absolute adherence was determined as PDC ≥ 95%.  
Data was collected using the CDC recommendation of Proportion of days to measure adherence 
(CDC, 2015). This was modified also to capture CD4 count, and Viral Load suppression as 
clinical markers for adherence. The Adherence tool was adapted to also capture Age, Gender and 
overall Clinical Outcomes such as Retained to care, Lost to follow up ( after 90 days of therapy) 
and death. Pharmacy refill records were used to identify adherence to diarized drug collections 
appointment dates. The data from pharmacy records was triangulated with data from clinical chart 
records as well as from an electronic data information management system, known as 3–Tier. 
Adherence was measured utilizing dispensing records following one month of treatment and the 
number of days the patient had missed their appointment. Adherence was measured on level of 
adherence over the last 84- day period measured at 3 durations of treatment: at 6 months, 12 
months and at 24 months. The Level of adherence was done for each of the two study groups.  
1.5.6.1.1 Proportion of Days Covered (PDC) 
Proportion of days covered (PDC) over the 84 day period was calculated from pharmacy records 
at 6 months (from the period of 4 months-6months of treatment), at 12 months (from the period 
of 10 -12 months of treatment) and 24 months (from the period of 22-24 months of treatment) ( 
Nau, 2009). 
PDC was calculated as: No of days medication is recorded as taken X 100 
                                          Total number of days in study period (84 days) 
 
1.5.6.1.2. Absolute Adherence 
A proportion of patients with PDC ≥ 95%, a standard set for anti-retroviral drugs as absolute 
adherence, was determined for each study group. Comparison of absolute adherence between the 
study groups was done at different treatment intervals, at 6 months, 12 months and 24 months.  
1.5.6.2 Data collection to determine association between Adherence and Gender: (Females and 
males as sub-groups) 
Comparison of adherence between females and males was done for each of the study groups to 
determine association between adherence and gender, using PDC and Absolute adherence (PDC 
≥ 95%) as adherence parameters. The comparison was also done at different time periods (6 
months, 12 months and 12 months) between the two genders. Retention in Care was also 
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determined for each gender, indicated by the number of patients remaining on treatment at 6, 12 
and 24 months. 
To determine clinical markers at initiation of treatment, the mean baseline Cd4 count was 
calculated for each study group. 
1.5.6.3 Data collection to determine immunological response for each study group. 
Patients’ clinical Chart records as well as an electronic Tier-dot net patient information system 
were used as source for clinical information. Viral load, Cd4 count and Clinical outcomes were 
used as indicators of immunological response for each patient. Laboratory information was used 
to triangulate data found in clinical records. 
1.5.6.3.1 Viral load Suppression 
Viral Load suppression was measured at 6 months, 12 months and at 24 months, for each of the 
study subjects. Viral load count of less than 400 copies per millilitre of blood, was considered as 
viral load suppression. The Viral Load suppression rate was measured for each of the groups at 6 
months, 12 months and 24 months of therapy. 
1.5.6.3.2 Change in Cd4 count  
Cd4 count was recorded at baseline, 6 months, 12 months and 2 months for each patient and mean 
Cd4 was calculated for each study group. Change in Cd4 (cells/mm3) was used as a measure of 
immunological response to treatment. 
1.5.6.3.3 Retention to care and death rates as Clinical Outcomes  
Clinical health records, Tier-dot net records and treatment adherence support records were used 
to determine retention to cate and death rates as clinical outcomes for each study subject. These 
were then tabulated for each study group, the proportion of patients retained in Care, the number 
and the proportion of patients that died whilst on treatment was determined at 6 months, 12 
months and 24 months for each study group, including those lost to follow up,  . 
1.5.6.4 Project Management  
Data was collected retrospectively. Pharmacists and Pharmacist assistants were trained for data 
collection and extraction of data from the data sources. A data Capturer was employed to capture 
data onto collation sheets and computers. 
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1.6 Data Analysis  
1.6.1 Statistical Analysis 
The data collected was entered into an Excel spreadsheet and analysed using the Statistical 
Package for the Social Sciences (SPSS Version 25) as recommended by Saunders et al. (2003). 
Data was analysed using descriptive statistics such as frequency and percentages with 95% 
confidence intervals. Categorical variables were presented as a frequency and percentage, 
together with tables or graphs. Associations were carried out where applicable using Pearson chi-
square tests. A p-value < 0.05 was estimated to be statistically significant. The researcher sourced 
the services of a statistician for the analysis of data. Services of medical officer were utilized assist 
with the analysis of laboratory results and Clinical Information. Interpretation was based on 
quantitative and qualitative data using triangulation.  
1.6.2 Validity, reliability and bias 
Validity 
The researcher established content validity by consulting with the research experts on the 
representativeness and suitability of data collection tools and questionnaires. Validity was tested 
during the pilot study and any gaps like unclear instructions were identified and rectified before 
the main study. 
Reliability 
Reliability is defined as the degree to which the data collection method will yield consistent 
findings, similar observations would be made or conclusions reached by other researchers. 
Saunders et al. (2003: 309). The Cronbach’s alpha was used to measure internal consistency. To 
ensure reliability of results, a simple random selection procedure was used to select study subjects 
from each of the study groups, from the total sample frame of subjects that met the inclusion 
criteria. The selection process for the study used a random sampling procedure to select health 
facilities from each of the 4 sub-districts; including urban, semi urban and rural facilities to ensure 
inclusivity of all patients from different socio economic classes. The data from pharmacy records 
was triangulated with data on clinical charts as well as from an electronic data information 
management system, known as 3 tier. Triangulation of information ensured reliability of data. 
Patients Lost to follow up were verified as such by Community Care Givers visiting the patients 
homes to ensure that the patients had not died. 
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Eliminating Bias 
To eliminate bias, the data collectors were trained to retrieve consistent, relevant information 
following predesigned data collection tools (appendices 7 and 8). Data collectors were external 
members to health care facilities selected for inclusion in the study. The procedure for sampling 
of health facilities ensured that patients were selected from all 4 levels of care, that is, a primary 
health care clinic, a community health care centre, a district hospital and a regional hospital. This 
was to ensure that the information was not biased to one level of care, or to one group of clinicians 
which might have limited competency in managing the patients compared to another. 
1.6.3 Data Management 
Information gathered was kept with the utmost confidentiality more so that the patients are HIV 
positive and needs to be treated with sensitivity. The study data was coded and therefore, not 
linked to the participant’s name. All study data was kept in a secure place and participant’s 
identity was not revealed during the study, and when publishing the results. On completion of the 
study, the data was destroyed. 
 
 1.7 Pilot Study 
A pilot study was conducted in one of the hospitals in UThukela District on approval of the 
research proposal by the ethics committee as well as the facility Chief Executive officers. The 
same tools that were used in the main study were used to collect data to ascertain the 
appropriateness of the tools and the validity of the data. A sample of 50 patients was selected from 
each study group to make a total study sample size of 100 cases. 
 
1.8 Ethical Considerations 
The study received ethical approval from the Biomedical Research and Ethics Committee of the 
University of KwaZulu-Natal under the reference number BE 084/15, as attached as appendix 3. 
Permission to conduct the study at health facilities and among HCWs was obtained from the 
Provincial DOH as well as the uThukela health district. All information was kept confidentially 
using patient codes instead of patient names, and the records were kept in password protected 
computers. After completion of the study, all data will be kept for 5 years and then destroyed by 
shredding. All data saved on password protected computer will be deleted. 
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 Permission Letters 
The researcher requested authority to conduct research in the public hospitals in UThukela District 
from the Head of Department, attached as appendices 2 and 3. Letters of consent were received 
from the hospital CEO’s who acted as gatekeepers for individual institutions (Appendices 4). 
Covering Information letter   
The researcher wrote a covering letter to the gate keepers and health facility managers explaining 
the procedures and the reasons for undertaking the research. The covering letter was sent out with 
the questionnaire and the data collection sheet and is attached as Appendix 5. 
Confidentiality and Anonymity 
The data collection process did not involve access to confidential personal data, including access 
to data for purposes other than this particular research project without prior consent of subjects. 
Researchers and assistants were sworn to confidentiality and participants were assured of 
anonymity and all the information provided was kept in confidence. The study data was coded 
and therefore, not linked to the participant’s name. All study data was kept in a secure place and 
participant’s identity was not revealed during the study and when publishing the results. The data 
obtained would be stored and ultimately disposed of after 5 years in a manner that would ensure 
confidentiality of the participants (Trochim 2006:2).  
Risks or Discomforts to the Participant   
No direct human participants were involved in the study and any health workers engaged in any 
manner in accessing data during the course of the study were not asked to perform any acts or 
make statements which might have caused discomfort, or compromise them, diminish their self-
esteem or cause them to experience embarrassment or regret. There were no adverse reactions 
experienced during the course of the study. The only slight discomfort the HCW respondents 
could have experienced was information provided regarding health systems and standard of 
practice of care within the department of health. The gate keepers were notified of this in the 
information letter. 
Research-related Injury  
There was no injury or anticipated belated injury to the HCW as they did not perform any acts. 
Therefore there was no compensation offered.  
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 1.9 Dissemination Plan 
Results of the study will be shared with the Uthukela with the facility managers and district 
Management teams through monitoring and evaluation meetings, and quality improvement 
forums. Information was shared with the research participant on completion of the HWC 
interview on health systems, on one-to-one basis, and with their operational managers. Any other 
relevant information pertaining to patient education will be shared with other patients and the 
community at health imbizos and through Sukuma Sakhe forums which are community structures 
based, in local municipalities that have representation with all the other government departments, 
including the department of social development. 
1.10 Layout / Structure of the thesis 
Chapter 1 outlines the introduction to the topic by providing information on the background as 
well as a literature review of existing studies regarding this topic. There is a statement of the 
problem, as well as research questions, the aim and objectives of this study. Information on the 
study design including, the study area, study design, statistical analysis and an ethics statement is 
also outlined. 
Chapter 2 is the research article which has been prepared according to submission guidelines to 
the Biomed Central Journal, entitled, “Comparison of adherence of fixed dose combination ARV 
drugs to multiple dose regimens in adult patients in public sector, uThukela District: a 
retrospective patient record review.” 
Chapter 3 is the research article which has been prepared according to submission guidelines to 
the Biomed Central Journal, entitled, “Impact of fixed dose combination ART drug regimens on 
viral load suppression and clinical outcomes in a rural setting in South Africa: a retrospective 
longitudinal study.” 
Chapter 4 is the synthesis and discussion of the significance of the findings of this study relating 
to adherence measured as proportion of days covered and absolute adherence, for treatment naïve 
patients on the fixed dose combination ART regimen compared to those taking multiple dose 
regimens, the effect of switching patients from multiple dose regimens to a fixed dose 
combination regimen, and the impact of the ART fixed dose combination on viral load 
suppression and clinical outcomes..   
The appendices are attached at end of this thesis. 
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In order to assess the impact of introducing a fixed dose combination regimen to improve 
adherence in South Africa a paper titled, “Comparison of adherence of fixed dose combination 
ARV drugs to multiple dose regimens in adult patients in public sector, uThukela District: a 
retrospective patient record review”  was prepared. The paper presented the results on 
assessment of proportion of days covered on treatment by patients on a tenofovir/emtricitabine/ 
efavirenz based fixed dose combination regimen and those on multiple dose regimens. A 
comparison was also made between females and males. A manuscript has been prepared 
following the guidelines of BMC Public Health and presented in chapter 2 below. 
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Abstract 
Background 
A fixed dose combination (FDC) Antiretroviral therapy regimen was introduced in South Africa, 
in 2013 to ensure that patients adhere to treatment and remain virally suppressed throughout their 
life. The aim of the study was to compare adherence between the new FDC regimen, and multiple 
dose regimens (MDC).The study also sought to find whether the FDC regimen was able to bridge 
the difference in adherence between males and females as was indicated in earlier studies for 
patients on MDC.  
Methods  
An institution based, adult patient retrospective pharmacy record review was conducted at four 
facilities at uThukela District, Kwa-Zulu Natal. Study subjects were 800 ART naïve patients 
initiated on treatment from January to December 2013, with 400 randomly selected from each of 
tenofovir/emtricitabine/efavirenz FDC and MDC regimens groups. Proportion of days covered 
(PDC) and absolute adherence ( PDC≥ 95%) were used as measure of adherence to treatment, 
calculated over a period of 84 days prior assessment at 6 , 12 and 24 months on treatment.  
Results 
At 0-6 months 85 patients switched from MDC to FDC, at 12 months a total of 220 had switched, 
and at 24 months 252 had switched (MDC-unswitched). Mean PDC at 6, 12 and 24 months for 
FDC group was (66± 30.29; 60± 34.27 and 54± 36.98 days out of 84 days) respectively, for MDC-
switched group (74±20.14; 70± 27.58 and 65± 33.59 days); and MDC-unswitched (59±36.85; 
34±39.96 and 22±36.99 days), with  difference significant with both groups when compared with 
FDC, p value<0.05. There was no significant difference in absolute adherence between the three 
groups at 6 months, p value >0.05. At 12 months PDC≥95% for FDC was 59.05% (222/376), 
MDC-switched 72.9% (159/218) and MDC-unswitched 36.4% (56/154), p value<0.05. At 24 
months FDC was 50.9% (189/3710, MDC-switched 71.1% (175/246) and MDC-unswitched 
23.3% (28/120), p value<0.05 with FDC. In the FDC group, mean PDC for females was 
(69±29.95; 64±32.4, and 57±35.14 days) and males (62±32.24; 53±37.25 and 46±39.87 days), p 
value<0.05 at 12 and 24 months.   
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Conclusions  
The study found that the newly introduced tenofovir/emtricitabine/efavirenz FDC regimen 
demonstrated higher adherence levels than MDC-unswitched ART regimens at 12 and 24 months. 
MDC-switched group demonstrated better adherence than FDC. Switching non-treatment naïve 
patients from a more complex regimen to a simpler FDC regimen resulted in even better 
adherence than those that were treatment naïve on FDC. FDC did not bridge the gender adherence 
gap. 
Keywords: Fixed Dose combination, Multiple Dose regimens, Adherence, ART regimen 
switches, Gender and ART adherence 
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Background  
As antiretroviral medicines become increasingly available and affordable for the treatment of 
human immunodeficiency virus (HIV) infected patients in South Africa, adoption of strategies to 
ensure that emergence of resistant strains of the virus are delayed, remains critical. These 
strategies include introduction of Fixed Dose Combination Antiretroviral therapy regimens that 
have been adopted to ensure that patients adhere to treatment, to optimise durability of present 
treatment regimens. Research on treatment adherence among most patients with chronic diseases 
suggests that increased complexity of medication regimens is associated with decreased 
adherence. Suboptimal adherence to antiretroviral therapy is well known to be the most common 
cause of virological failure of HAART. Successful treatment of HIV infection/acquired 
immunodeficiency syndrome (HIV/AIDS) with highly active antiretroviral therapy (HAART) 
requires that patients maintain nearly perfect adherence to the prescribed regimen (Stone, 2001).  
Since the introduction of HAART in the public sector in South Africa in 2004, only multiple dose 
regimens were used, initially based on Stavudine as the main Nucleotide Reverse Transcriptase 
of choice, often interchanged with Zidovudine (NDOH Anti-retroviral Guidelines, 2004). Later 
on Tenofivir based regimens were introduced and Stavudine use reduced to improve ART toxicity 
profile due to Stavudine. The Fixed Dose Combination that is Tenofivir based was introduced 
with the purpose of reducing drug toxicities, improving patient adherence and to reduce treatment 
cost to Anti-retroviral treatment (ART) (Davies, 2013). 
The implementation of the new fixed Drug Combination regimen that was introduced in 2013 by 
the Department of Health is Tenofivir-based, (containing Tenofivir 300mg, Emtricitabine, and 
Efivarenz 600mg) with the one tablet only taken in the evening, but some of the prescribers 
delayed the implementation and retained the older treatment guidelines, prescribing multi-dose 
regimens. 
A meta-analysis study done in South Africa (SA) demonstrated the inverse relationship between 
medication adherence and dosing frequency, with once daily dosing associated with the greatest 
adherence (Srivastava et al, 2013).  A study done in Colorado, USA (Langness et al, 2015) found 
that PDC on a single regimen of PLWH taken once-daily was significantly higher than PDC for 
multi-tablet once-daily regimens or multi-tablet twice-daily regimens. At uThukela District the 
Lost to follow up rate to first line multiple dose regimens in 2012, prior to implementation of the 
FDC regimen was as high as 17% on average, ranging between 8% and 28 % at different facilities 
(uThukela District health plan, 2013). Because ART regimens involve taking multiple drugs, 
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combining these into one pill taken once daily, thus reducing the pill load and reducing the dosing 
frequency should have desired outcomes of improved adherence (Deeks et al, 2010). 
Disadvantages of fixed drug combinations include reduced flexibility in dosing, exposure of 
patients to drugs that they do not need possible increased risk of adverse side effects, without 
increase in therapeutic benefit (Serebruany, 2008). Fixed dose combinations and once a day 
dosing regimens may also result in higher peaks of drug concentration reached that might result 
in toxic doses reached and increased side effects and adverse reactions of the drugs. These in turn 
if not monitored may reduce the intended improved adherence. 
There are some advantages in using multiple dose regimens, including ease in identification of 
the causal drug when patients experience side effects. Giving doses in multiple dose tailored for 
the drugs half- life, may reduce chances of this happening. With multiple dosing a clinician is 
able to vary the dose of drug given and allows individualized patient management and flexibility. 
It is also much more difficult to explain complex regimens to patients thus compromising correct 
dosing and pill identification.  
Findings of a study done at kwaThema in SA (Melaku et al.2016), before the use of FDC, showed 
that self-report adherence assessments of patients on ART indicated that 82.8% adhered to 
treatment while 17.2% did not. Females had an adherence of 80.2% compared to that of males 
which was 69.9%.  
Research has shown that a fixed dose combination of generic TDF/FTC/EFV is effective and able 
to achieve viral suppression of 96% at 6 months for ARV –naïve and experienced patients, and 
that it is safe to use in those with no co-morbid conditions (Pujari et al, 2008). Other studies 
showed advantage of using fixed dose combination over those regimens with more complex or 
frequently administered regimens (Deeks et al, 2010). A study in USA by Sax et al. (2012) 
observed that only 47% of patients achieved a 95% adherence when taking 1 pill a day, versus 
41% - 34% taking 2-3 pills a day. It was hoped that introducing the fixed Dose combination, thus 
reducing the pill burden of the first-line regimen to 1 pill once daily would improve adherence 
levels. 
The Adherence Curve Theory assumes that at the start of therapy patients become motivated to 
adhere to their treatment, and often times this is supported by strong patient-provider relationship 
that is often demonstrated at the start of therapy. This motivation plateaus around 21 weeks after 
which this motivation declines with time as the patient gets better, and the support provided by 
clinicians also declines (Friedland, 1999). The rationale of conducting the study was to assess if 
  
38 
 
 
there was significant difference in adherence between the fixed dose combination ART regimen 
and the multiple dose regimens. Some of the clinicians were initially reluctant to switch patients 
that they considered clinically stable on multiple dose regimens and were slow in switching 
patients to FDC. The study sought to find if there was any rationale to this thought. The study 
also sought to find whether the introduction of the Fixed Dose combination had any impact on 
the difference between males and females as was indicated in studies for patients on multiple dose 
combination regimens. 
Methods 
Study Design   
An institution based, retrospective patient record review was conducted at 4 Health facilities of 
Uthukela District, Kwa-Zulu Natal. 
Study area and Period 
The study was conducted from January 2016 to December 2017 at four Health facilities that were 
rendering comprehensive ART services. 
Source and study population 
Patient record retrospective reviews of adult patients who were ART naïve on initiation of 
antiretroviral therapy were conducted. The study subjects were initiated on the 1st line treatment 
regimen according the South African ART Treatment guidelines (2013). The study subjects were 
randomly selected from 4 health facilities in the district, stratified to allow one facility from each 
level of care, to include: 1 Regional hospital (RH),1 district hospital (DH), 1 Community Health 
Centre ( CHC),  and 1 Primary health care facility ( PHC)   randomly selected from the 4 local 
municipalities that make up the district. 
Study subjects were stratified according to the two groups:  
Group 1: Patients initiated on Fixed Dose Combination (FDC) ART regimen; of Tenofivir, 
Emtricitabine and Efivarenz, taken once a day. 
Group 2: Patients initiated on any other multiple- dose ART regimen. 
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 Inclusion Criteria 
Study subjects were Adult patients (above 18 years of age) who had been on 1st line ARV 
treatment. Only those patients who were ARV naïve on initiation of ART therapy were included 
in the study. 
Sampling Procedure 
Sampling of Facilities 
Data was collected  from 4 health facilities in the district, one facility at each level of care, to 
include: 1 Regional hospital,1 district hospital, 1 Community Health Centre, and 1 Primary health 
care facility randomly selected from the 4 sub-districts  using stratified random selection from the 
4 local municipalities in the district. 
Procedures for selection of Study Subjects 
Study subjects were patients who started ART therapy in January 2013 to December 2013. The 
subjects were selected from each of the 4 study facilities, and were stratified according to the 
ARV treatment regimen they have been initiated on. Patient files were selected based on start 
date, and age, selected only patients 18 years and older. Only patients that remained on treatment 
beyond the first 3 months of treatment were included in the initial cohort. This cohort formed a 
baseline of 400 patients on FDC and 400 on MDC. Only study subjects on 1st line ART regimen 
were selected and stratified into two groups as follows:. 
Group 1: Patients on Fixed Dose ARV combination of Tenofivir, Emtricitabine and Efivarenz, 
taken once a day. 
Group 2: Patients on multiple- dose, 1st line ART regimens. 
Study participants were sampled from a total sample frame of 4357 patients over the same period 
as the FDC group. One patient on the study later found to be younger than 18 years, and was 
excluded from the study, leaving a total sample size of 399 patients.  
Sample Size 
Using a formula by Naing et al, a minimum of 328 participants for each regimen group was 
required to detect at least 10% difference, a power of 80%, and 95% confidence interval. The 
sample size was estimated by using the formula: n = P (1-P) (Z-α/2/E), where P = total number 
of clients on treatment, (Z - α/2) = a constant code representing 95 % of confidence [1.96], E = 
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margin of error [+/- 0.05] (Glenn, 1992). An assumption was made to detect at least 10 % (P = 
10%) using the above formula. To accommodate for loss to follow up and drop outs 20% was 
added to the minimum sample size, a maximum of 400 participants per study group was used in 
this study. A total sample size of 400 patients on Fixed Dose regimen and 400 patients on multiple 
dose regimens were included in the final assumption of the sample size. A total Sample size of 
800 participants formed the cohort for the study. This maximum sample size was divided among 
the four facilities included in the study. 100 patients were randomly selected from each of the 4 
facilities for fixed dose combination and multiple dose regimens, respectively, using the formula 
( n+×)  based on total number of patients per type of regimen in each facility. For example for 
facility identified as PHC, with 341 patients on multiple dose, the formula n+3 was used for 
selecting 100 clinical chart records. 
Data Collection tools and Procedures 
Proportion of days covered was used as Quasi Objective measure of adherence to treatment,  
calculated as a ratio of tablets that were in the patients possession compared to the actual number 
of tablets they should have had over a certain period. For this study this was measured over an 84 
day period, using pharmacy dispensing medication collection history. Absolute adherence was 
determined as PDC ≥ 95%. 
Data was collected using a pretested structured data collection tool administered by 3 trained 
health care workers. The tool was adapted from CDC (2015) to calculate Proportion of days 
covered to measure Adherence, and modified to cater for different regimens.  Pharmacy refill 
records were used to identify adherence to diarized drug collections appointment dates. The data 
from pharmacy records was triangulated with data from clinical chart records as well as from an 
electronic data information management system, known as 3–Tier. Adherence was measured 
utilizing dispensing records following one month of treatment and the number of days the patient 
had missed their appointment. Adherence was measured on level of adherence over the last 84- 
day period measured at 3 durations of treatment: at 6 months, 12 months and at 24 months. The 
Level of adherence was done for each of the two study groups. The Clinical Chart records as well 
as the 3-Tier patient information system as used as source for records on Cd4 count as a clinical 
marker.  
The Adherence tool was adapted to also capture Age, Gender and overall Adherence Outcomes  
a) To determine Patient adherence to ART treatment between the two study groups, FDC and 
MDC  
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i) Proportion of days covered (PDC) over the 84 day period was calculated from pharmacy records 
at 6 months (from the period of 4 months-6months of treatment), at 12 months (from the period 
of 10 -12 months of treatment) and 24 months (from the period of 22-24 months of treatment).  
PDC was calculated as:  No of days medication is recorded as taken X100 
                                          Total number of days in study period (84 days) 
 
ii)A proportion of patients with PDC > 95% as Absolute adherence, was also determined for each 
study group. 
iii) Comparison of Adherence between the Different treatment duration periods of ART Initiation 
b)  To determine association between Adherence and Gender: (Females and males as sub-groups) 
Association between PDC and Gender, and Absolute adherence (PDC > 95%) was also 
determined at different time periods (6 months, 12 months and 12 months), and between the two 
groups. 
To determine clinical markers at initiation of treatment, the mean baseline Cd4 count was 
calculated for each study group. 
Data Quality assurance 
Data was collected by using a pre-tested tool by trained health care providers. There was 
continuous supervision to control the data collection procedure. All the data, from each study site, 
was checked by the principal investigator, for completeness, clarity and consistency. The different 
sources of data were used for triangulation. Data was intensively cleaned before analysis.  
Data processing and analysis 
Data was coded and entered into different statistical tools, including Enterprise Miner and SPSS 
windows version 20 for further analysis. Adherence to HAART was assessed by using Proportion 
of days covered (PDC) calculated from using Pharmacy refill records and 3-Tier records. 
Absolute Adherence was measured by working out the number of days covered above 95%. The 
age was calculated using the median and standard deviation. Bivariate logistic regression was 
used to check variables associated with the dependent variable. Odd ratios with 95% CI were 
computed and those variables found to have p-values of < 0.05 were considered significantly 
associated with the dependent variable. T-tests were used to find evidence of a significant 
difference between population means. The t-value of 1.968-1.96 was used to determine 95% level 
of confidence of difference between 2 population means.  
  
42 
 
 
Adherence assessment was done from month 4 to month 6 (over a period of 84 days), for month 
6, from 10-12 months for month 12, and from 22-24 months for month 24. Those patients that 
had died were excluded from the total cohort when determining outcomes for a particular period. 
Triangulation of information from the clinical chart records as well as the electronic 3-Tier record 
system was used to determine if the patient was still at the facility, and all “transfer outs” were 
excluded from the study. On calculating adherence, all patients that could be traced by CCG’s 
and found to be still alive were regarded as defaulters and were included in the analysis of 
adherence, and only the proportion of days covered (PDC) was calculated based on number of 
days when they possessed medication as a percentage of adherence over the period of review (84 
days), at 6, 12 and 24 months respectively. Patients lost to follow up were regarded as defaulters, 
and these patients were included in the study in the calculation of adherence, assuming zero PDC. 
If the records on follow up by CCG’s showed that the patient had died, the patient was regarded 
as an exclusion on calculation of adherence.  
Ethical Considerations 
Ethical clearance was obtained from the ethical review Committee of the University of Kwa-Zulu 
Natal. Permission was granted by the Provincial Department of Health. Approval was granted by 
the Uthukela District Director and the CEO’s of the Health facilities, and letters of support were 
provided. Each caregiver and operational manager of the facilities or ART unit was adequately 
informed about the purpose of the study. Patient information was kept confidentially using patient 
codes instead of patient names, and the records were kept in password protected computers.  
Results 
Socio-demographic characteristics of the study subjects 
Two groups of patients, on FDC and MDC, were included in this study. At baseline there were 
400 participants from each group. The majority of the participants in both groups were females; 
with 67.5% (270/400) in the FDC group and 59.3% (237/400) in the MDC group .The median 
age of the FDC group was 33.1 ± 10.3 years while the median age for the MDC group was 32.9 
± 10.1 years. 
Between 0 and 24 months of treatment from the MDC group, a total of 252 participants were 
switched to Fixed Dose Combination regimen and identified as MDC Switched. Multiple Dose 
group was assessed as two distinct sub-groups, those that switched to FDC and those that did not 
switch and remained on MDC. The assessment of adherence was conducted comparing the 3 
groups: FDC, MDC Switched and MDC Unswitched. 
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From the total of 400 prescriptions from the Multiple Dose combination group was comprised of 
7 % Abacavir based multiple regimens, 5.25% Stavudine, 3.25% Zidovudine and 84.5 % 
Tenofivir based.  These were sampled from a total sample frame of 4357 patients over the same 
period as the FDC group. Two patients on the FDC group was found at 24 months to have changed 
to a second line regimen and was excluded from the 24 month assessment.  
Clinical Marker at baseline of the study subjects 
At baseline, the mean Cd4 count was 181±123.87 cells/ mm3 for FDC (n=356) and 186±127.53 
Cd4 cells/mm3 for MDC (n=337), there was no significant difference between the 2 group Mean 
Cd4 (p value =0.623). 
Table 2.1 presents the change in regimen of participants on FDC and MDC groups over time. At 
the end of 6 months 85 out of 400 participants were changed from the multiple dose regimen to 
the fixed dose, leaving 315 remaining on the MDC. Between 7 months and 12 months, an 
additional 135 were further switched to FDC and finally 32 more were switched between 13 and 
24 months. There were no changes in the FDC except for two participants who changed to second 
line. 
Table 2.1: Change of regimen of study participants over time   
  
Duration 
on 
treatment 
FDC Group (N=400) MDC Group (N=400) 
FDC 
unswitched 
FDC 
Switched 
MDC 
Unswitched 
MDC 
Switched 
Baseline 400 Nil 400 Nil 
0- 6 
months 
400 Nil 315 85 
7-12 
months 
400 Nil 180 220 
13-24 
months 
398 2 148 252 
Total at 24 
months 
398 2 148 252 
 Legend:  FDC=fixed dose combination, MDC=multiple dose combination regimen 
Adherence Assessment 
Proportion of Days Covered 
Mean Proportion of days Covered for FDC, MDC Unswitched and MDC Switched over 
time 
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Table 2.2 represents the Mean Proportion of days covered for FDC, MDC Switched and MDC 
Unswitched groups at 6, 12 and 24 months calculated over a period of 84 days. Mean PDC was 
significantly higher for the MDC switched Group than FDC or MDC Unswitched at all 3 intervals, 
p value < 0.05. Mean PDC for FDC was in turn higher than MDC Unswitched at all 3 intervals 
on treatment.  Mean PDC for all the groups was below the acceptable standard of 95% PDC 
(equivalent to 80 days). Mean PDC declined over time for all 3 groups, with mean PDC for MDC 
unswitched being 22 days out of 84 days at 24 months.  
Table 2.2: Mean Proportion of days Covered for FDC, MDC Unswitched and MDC Switched 
over time 
Duration 
of time on 
Treatment 
Mean PDC for 
FDC      ( out 
of 84 days) 
Mean PDC for 
MDC Switched                        
(out of 84 days) 
p value
Mean PDC for 
MDC 
Unswitched                    
( out of 84 
days) 
p value 
6 months 
66 ± 30.29(n= 
377) 
74 ±20.14 ( n= 
84) 
0.0213* 
59±36.85 ( 
n=292) 
0.0095* 
12 months 
60 ± 34.27( 
n=376) 
70 ± 27.58 ( 
n=218) 
0.0006* 
34 ± 39.96 ( 
n=154) 
<0.0001* 
24 months 
54 ± 36.98 
(n=371) 
65 ± 33.59 ( n= 
246) 
<0.0001* 
22 ± 35.99 ( 
n=120) 
<0.0001* 
Legend: PDC=proportion of days covered, FDC=fixed dose combination, MDC=multiple dose 
combination. * Statistically significant when compared to FDC. 
Comparison of Absolute Adherence between FDC, MDC Switched and MDC Unswitched 
At 6 months 
Table 2.3 presents the Proportion of participants at different levels of adherence for FDC, MDC 
switched and MDC-unswitched groups. Absolute adherence (PDC≥95%) at 6 months for FDC 
was 65.5% (247/377), for MDC switched 73.8% (62/84) and MDC-unswitched 64.73% 
(189/292). The results suggest that participants with PDC ≥95% were not significantly different 
between the FDC and MDC Switched, p value>0.05 and between FDC and MDC Unswitched 
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groups, p value > 0.05. At adherence levels ranging from 80-79%, the proportion of participants 
for FDC was significantly higher than MDC Unswitched (p value < 0.05).  
The proportion of participants with PDC less than 50%, on FDC, PDC was 18.9% (68/377), for 
MDC switched 7.1% (6/84) and MDC unswitched 29% ( 85/292). The results suggest that the 
proportion of participants at this low level of adherence was significantly higher for MDC 
Unswitched than FDC than MDC, p value < 0.05. The proportion of participants for FDC was in 
turn higher than that of MDC switched, this was statistically significant (p value < 0.05) at this 
level of adherence. 
At 12 months 
PDC ≥ 95% for FDC was 59.04% (222/376), for MDC switched was 72.9% (159/218) and MDC 
unswitched it was 36.4% (56/154). The results suggest the difference between MDC switched and 
FDC was significant, p value< 0.05. PDC ≥95% was significantly higher for FDC than MDC 
unswitched, p value < 0.05.  
The results suggest that the proportion of participants with PDC less than 50% increased with all 
three groups at 12 months. The proportion of participants was 25% (94/376) with FDC, 16.1% 
(35/218) with MDC switched and 58% (90/54) with MDC switched. The differences between 
these groups were significant, p value < 0.05. 
At 24 months 
The proportion of participants with PDC ≥ 95% for FDC was 50.94% (189/371), for MDC 
switched was 72.9% (175/246) and MDC unswitched 23.3% (28/120). The results suggest that 
the difference between MDC switched and FDC was statistically significant, p value< 0.05. PDC 
≥95% was significantly higher for FDC than MDC unswitched, p value < 0.05. For PDC < 50%, 
the results suggest that the proportion of participants for all three groups at 24 months further 
increased at 24 months. The proportion of participants at this level of adherence was 33.2% 
(123/371) with FDC, 21.5% (53/246) with MDC switched and 73.3% (88/120) with MDC 
switched. The differences between these groups were significant, p value < 0.05. 
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Table 2.3 Comparison of proportion of days covered to proportion of participants 
Comparison of PDC and Absolute Adherence over time between FDC, MDC Switched and 
MDC Unswitched 
Table 3: Comparison of Proportion of days coverted to proportion of participants
PDC  FDC  95%CI
MDC 
Switched 
95%CI p value
 MDC 
Unswitched
95%CI p value
65.50% 73.81% 0.1443 64.73% 0.8336
(n=247) (n=62) (n=189)
5.57% 2.38% 0.2262 2.05% 0.022
(n=21) (n=2) (n=6)
9.28% 15.48% 0.0929 3.77% 0.0051
(n=35) (n=13) (n=11)
1.59% 1.19% 0.7871 0.34% 0.1164
(n=6) (n=1) (n=1)
18.04% 7.14% 0.0139 29.11% 0.0007
(n=68) (n=6) (n=85)
N 377 84 292
T/O 1.5% (n=6) 0.69-3.23 1.18% (n=1) 0.02-6.37 0.8181 0.95% (n=3) 0.32-2.76 0.5157
Died 4.25% % (n=17)2.67-6.7 0% (n=0) 0.00 - 4.32 0.0536 6.35% (n=20) 4.15-9.60 0.2076
Total 400 85 315
PDC  FDC  95%CI
MDC 
Switched 
95%CI p value
 MDC 
Unswitched
95%CI p value
59.04% 72.9% 0.0007 36.4% 0.0076
(n=222) (n=159) (n=56)
5.85% 3.2% 0.1498 0.6% 0.0512
(n=22) (n=7) (n=1)
8.78% 6.9% 0.4122 3.9% 0.5029
(n=33) (n=15) (n=6)
1.33% 0.9% 0.6527 0.6% <0.0001
(n=5) (n=2) (n=1)
25.00% 16.1% 0.0108 58.4%
(n=94) (n=35) (n=90)
N 376 218 154
T/O 1.5%(n=6) 0.69-3.23 0.91% (n=2) 0.25-3.25 0.5353 1.11% (n=2) 0.3-3.96 0.7114
Died 4.5% (n=18) 2.87-7.00 0% ( n=0) 0.0-1.72 0.0001 13.33% (n=24) 9.12-19.07 0.0001
Total 400 220 180
PDC  FDC  95%CI
MDC 
Switched 
95%CI p value
 MDC 
Unswitched
95%CI p value
50.94% 71.1% <0.0001 23.3% <0.0001
(n=189) (n=175) (n=28)
5.4% 2.4% 0.07346 1.7% 0.08726
(n=20) (n=6) (n=2)
9.4% 4.1% 0.01208 0.8% 0.00168
(n=35) (n=10) (n=1)
1.1% 0.8% 0.7414 0.8% 0.8181
(n=4) (n=2) (n=1)
33.2% 21.5% 0.00174 73.3% <0.0001
(n=123) (n=53) (n=88)
N 371 246 120
T/O 2.0% ( n=8) 1.02-3.92 1.59% (n=4) 0.62-4.01 0.69654 1.35% (n=2) 0.37-4.79 0.5892
Died 4.75% (n=19) 3.07-7.33 1% (n=2) 0.22-2.84 0.00512 17.57% (n=26) 12.28-24.50<0.0001
Total 400 252 148
<50%
28.55-
38.09
16.86-
27.09
64.78- 
80.43
6 months
12 months
24 months
65-79% 6.86-12.83 2.23-7.33 0.15- 4.56
50-64% 0.42-2.74 0.22-2.91 0.15 -4.56
≥95%
45.87-
55.99
65.19-
74.44
16.66-
31.65
80-94% 3.52-8.18 1.12-5.22 0.46-5.88
50-64% 0.57-3.07 0.25-3.29 0.11-3.59
<50%
20.89-
29.61
11.78-
21.51
50.54-
65.93
80-94% 3.89-8.7 1.56-6.48 0.11-3.59
65-79% 6.32-12.07
4.21-
11.04
1.8-8.24
<50%
14.49-
22.24
3.31-
14.72
24.2-
34.56
≥95% 54-63.89
66.68-
78.4
29.18-
44.2
65-79% 6.75-12.63 9.28-2.47 2.12-6.62
50-64% 0.73-3.43 0.21-6.44 0.06-1.91
≥95%
60.59-
70.14
63.52-
82.02
59.09-
69.99
80-94% 3.67-8.36 0.65-8.27 0.94-4.4
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Figure 2.1 indicates that in all groups, the proportion of patients with PDC ≥ 95% (Absolute 
Adherence) reduced with time from 6 months, 12 months to 24 months, with the least reduction 
noted in the MDC Switched group. At all intervals the proportion of participants with PDC ≥ 
95% was higher for MDC Switched group than either FDC or the MDC unswitched groups. The 
rate of decline in PDC≥ 95% over time was much higher for the MDC Unswitched group. 
 
Figure 2.1: Absolute adherence (PDC ≥95%) on FDC, MDC Switched and MDC Unswitched 
groups over time. Legend: PDC=proportion of days covered, FDC=fixed dose combination, 
MDC=multiple dose combination regimen  
Differences in Proportion of Days Covered between females and males  
Table 2.4 presents differences in mean PDC in days, between females and males at months 6, 12 
and 24, with FDC, MDC Switched and MDC Unswitched groups. In the FDC group, mean PDC 
for females was (69±29.95; 64±32.4, and 57±35.14 days) and males (62±32.24; 53±37.25 and 
46±39.87 days). The results suggest that for the FDC group, mean PDC for females was higher 
than that of males, but was only statistically significant at 12 and 24 months, p value< 0.05.  In 
the MDC Switched group, males had a mean PDC higher than that of females, but at 12 and 24 
months females had a higher mean PDC, but the difference was not statistically significant, p 
value >0.05. Again, mean PDC for males in the unswitched group was higher than that of females 
at 6, 12 and 24 months; however the difference was not statistically significant, p value > 0.05. 
Table 2.4 suggests that with both genders in the three groups, Mean PDC declined with time. 
Table 2.4: Differences in mean PDC amongst females and males  
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Legend: PDC=proportion of days covered, FDC=fixed dose combination, MDC=multiple dose 
combination regimen.*statistically significant between the two genders  
 
Differences in Absolute Adherence between Females and Males 
Table 2.5 presents differences in Proportion of Absolute Adherence between females and males 
for the 3 study groups at months 6, 12 and 24 months. The results suggest that the proportion of 
participants with Absolute Adherence (PDC ≥95%) was significantly higher for females than 
males on the FDC regimen at 6 and 12 months (68.3% vs 59.3%, and 62.5% vs 51.3 % 
respectively), p value< 0.05. No significant difference was noted between the two genders at 24 
months. The proportion of participants with Absolute Adherence was higher for females than 
males on the MDC Switched regimen at 12 and 24 months, the difference between the two genders 
was not statistically significant, p value> 0.05. Absolute adherence at 6 months for males in the 
MDC Unswitched group was significantly higher than that of females, p value < 0.05; however 
at 12 and 24 months for this group there was no significant difference noted in absolute adherence 
between the two genders. 
Duration 
on 
Treatmen
t in 
months 
 Means of PDC 
with FDC out of 84 
days 
p-
value 
Means of PDC with 
MDC Switched out 
of 84 days 
p-
value 
Means of PDC 
with MDC 
Unswitched out of 
84 days 
p-value 
Females Males  Females Males   
Female
s 
Males   
6 
68±29.2
5 
(n=259) 
62±32.2
4 
(n=118) 
0.9353 
72±22.8
7 (n=58) 
79±10.9
6 (n=26) 
0.146
2 
57±37.9 
(n=166) 
62±35.3
4 
(n=126) 
0.2944 
12 
64±32.4
0 
(n=259) 
53±37.2
5 
(n=117) 
0.0068
* 
71±27.1
6 
(n=135) 
68±28.2
9 (n=83) 
0.390
7 
31±39      
(n=98) 
38±40.7
3 (n=77) 
0.255 
24 
57 ± 
35.14 
(n=256)  
46 ± 
39.87 
(n=115)  
0.0067
* 
66 ± 
32.79 
(n=147)    
63 ± 
34.85 
(n=99)   
0.506
7 
20 ± 
34.62 
(n=71)  
25 ± 
38.02 
(n=49)   
0.4218 
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Table 2.5:  Differences in proportion of Absolute Adherence (PDC≥95%) between females and 
males 
 
Legend:  FDC=fixed dose combination, MDC=multiple dose combination regimen * statistically 
significant when compared to FDC 
Discussion 
The results were presented using Mean PDC at 6, 12 and 24 months for the 3 study groups, FDC, 
MDC Switched and MDC Unswitched, calculated over a period of 84 days at each study period. 
Absolute Adherence was defined as PD ≥ 95%, a standard acceptable for patients on ART to 
ensure viral suppression (Kim et al. 2014). In this study, a comparison of the level of adherence 
was done between the FDC regimen and the Unswitched MDC regimen, and between FDC and 
the MDC Switched regimen. A comparison of adherence was also done between females within 
each of the groups. Retention in care was reported indicated by number of clients who were 
retained on treatment, the number of those that were lost to follow up after 90 days and those that 
died whilst on ART treatment. 
The study found that in spite of the implementation of a Fixed Dose Combination regimen mean 
PDC   for FDC was below the acceptable standards of 80% for general medicines and, was below 
the Absolute adherence standard of 95% for antiretroviral treatment. The proportion of 
participants demonstrating Absolute adherence was only 65.5% for FDC at 6 months, which 
declined to 59% and 50.9% at 12 and 24 months respectively. Although these results show 
improvement from adherence levels indicated in earlier studies done in similar rural setting in SA 
before the introduction of FDC (Van Dyk , 2011)which found that only 40% of clients were able 
to achieve absolute adherence on ART, this is still lower than other African studies where 
adherence was found to be 77%, and comparable to rates in developed countries (Eyasu, 2015).   
Females  95%CI Males  95%CI Females  95%CI Males  95%CI Females  95%CI Males  95%CI
68.3% 62.24-
73.7
59.3% 50.3-
67.75
70.7% 57.99-
80.82
80.8% 62.12-
91.49
63.3% 55.69-
70.21
66.7% 58.05-
74.3
(n=177) (n=70) (n=41) (n=21) (n=105) (n=84)
62.5% 56.51-
68.22
51.3% 42.33-
60.15
77.0% 69.26-
83.33
66.3% 55.58-
75.52
62.5% 23.3-
43.57
51.3% 30.74-
53.73
(n=162) (n=60) (n=104) (n=55) (n=28) (n=28)
53.5% 47.4-
59.53
45.2% 36.42-
54.32
73.5% 65.8-
79.94
67.7% 57.96-
76.08
19.7% 12.13-
30.42
28.6% 17.85-
42.41
(n=137) (n=52) (n=108) (n=67) (n=14) (n=14)
6 months
12 months
24 months
<0.0001*
0.2187
0.25848
0.01078*
0.0394*
0.13888
0.332
0.0819
0.3271
Duration 
on 
Treatment 
p-value p-value p-value
Absolute Adherence ( PDC ≥95%)  
proportions on FDC
Absolute Adherence ( PDC ≥95%)  
proportions on MDC Switched
Absolute Adherence  ( PDC ≥95%) 
proportions on MDC Unswitched
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Of interest, a finding of this study indicated that the group that switched from multiple dose 
regimens to Fixed Dose regimen had an Absolute Adherence that surpassed that of the FDC group, 
with this being statistically significant at 12 and 24 months.  The level of adherence for this group 
was almost constant over time, indicating low decline from 6 months to 24 months. This finding 
suggests that as these patients were no longer naïve when switched to a regimen with a much 
reduced pill load, from a more complex regimen, adherence improved for these patients compared 
to their previous peers on MDC and also surpassed those started on FDC. The effect of revived 
motivation by experienced patients starting a more simplified regimen could be an explanation 
for the improved adherence for these patients as explained by Schroeder et al. (2004), who 
conducted a Cochrane systematic review of adherence on patients on blood pressure medication 
which found that simplifying a drug regimen resulted in relative increase in adherence from 8 to 
19 % (almost two-fold). 
This study demonstrated that there was a significant difference in mean PDC and absolute 
adherence between fixed dose combination and multiple dose combination unswitched group, at 
12 and 24 months.  This was in agreement with another study done previously that showed 
advantage of using fixed dose combination over those regimens with more complex or frequently 
administered regimens (Deeks, et al, 2010). This  above finding was  also in agreement with the 
Colorado study in USA (Langness et al, 2015) and the meta-analysis study done in South Africa 
(Srivastava et al, 2013) which demonstrated the more complex the regimen, the less adherent the 
patient to the treatment. 
However, this study found that at 6 months, absolute adherence was not significantly different 
between the FDC and MDC Unswitched group. Other factors related to non-adherence at start of 
treatment on FDC could have compromised the expected level of adherence early on in treatment, 
in support of Haochu’s findings that side effects and drug toxicity could compromise adherence 
(Haochu, 2018). Patient- provider relationships, adherence support provided as well as other 
health systems issues related to access to health services are additional factors that compromise 
adherence to treatment (Naidoo, 2011). 
Mean PDC and Absolute Adherence for FDC and MDC unswitched in this study declined over 
time, with the worst adherence demonstrated at 24 months.  This finding is in agreement with a 
meta-analysis study done in South Africa that showed that persistence on treatment to oral 
therapies with both single dose and multiple dose regimens declined with time, with no significant 
differences noted between the two regimens over time (Srivastava et al, 2013). In this study 
however, absolute adherence on MDC unswitched group declined faster than FDC and MDC 
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Switched groups. Even though MDC Unswitched group had equal adherence rates with FDC and 
MDC switched at 6 months, persistence of adherence declined much more than FDC at 24 months. 
Medication persistence is said to be determined by primary adherence at start of treatment (Raebel 
M. et al., 2013). Persistence on treatment on the MDC Switched group remained high.  
This study demonstrated a significant difference in mean PDC between males and females only 
for FDC group at 12 and 24 months, but not at 6 months. Absolute adherence was significantly 
higher for females in the FDC Group, but was found higher for males than females in the MDC 
unswitched group, though this was statistically not significant. This suggests that females are less 
able to adhere to more complex treatment regimens, however as time progressed to 24 months 
there was no significant difference in adherence between the two genders.  The superiority of 
females over males in absolute adherence for FDC at 6 and 12 months is in agreement with 
Melaku’s study conducted in Kwa-Thema SA in 2016 ( Melaku et al. 2016). Although the Kwa-
Thema study was not able to distinguish between the different treatment regimens used by the 
participants; in this study the findings of females being more adherent to ART than males could 
not be confirmed with MDC Switched and MDC Non switched groups. Absolute adherence in 
this study was relatively lower than the kwa-Thema study for both females (80.2%) and males 
(69.9%). This may be due to the methods used to assess adherence which was mainly self- reports 
by study participants in the Kwa Thema study, while this study used Proportion of days covered 
by patients 
This study found that there was a progressive increase in the numbers of participants switched 
from MDC to FDC, from 102 after 6 months, to 255 at 12 months, and to 288 at 24 months. This 
suggests that there was compliance, though slow, with the ART treatment guidelines stating the 
use FDCs for patients on first line regimen (SA HIV/AIDS Treatment guidelines 2013). 
Strengths and limitations of the study  
The sample size of the study with 800 participants was relatively representative of the population 
of FDC and MDC treatment in the district under study with 26 461 patients on ART treatment at 
the time of data collection (SA District Health Information Systems, 2013). The sample size was 
estimated by using the formula as discussed by Glenn, 1992.  
As part of the limitations, this study did not investigate other factors contributing to barriers to 
adherence to treatment other than pill count, and gender, including presence of side effects and 
adverse drug reactions on the different drug regimen, as safety and toxicity are also known to be 
significant factors contributing to non-adherence. This was due to incompleteness of clinical 
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information recorded by clinicians in the patients’ health records. A triangulation of data collected 
using patient interviews would have assisted in determining other factors contributing to non- 
adherence other than complexity of regimen and the frequency of doses taken.  
Conclusions 
This study demonstrated that adherence to treatment on the fixed dose combination ART regimen 
was significantly better than that of treatment-naïve ART patients on multiple dose regimens. 
There was a high proportion of days covered and better retention to care with FDC compared to 
MDC regimen; however, absolute adherence was only significantly higher for the FDC regimen 
after 6 months of starting ART. This study also found that switching patients from a more complex 
regimen to a simpler regimen with less pill load and dosing frequency resulted in even better 
adherence for those patients, than those that were treatment naïve on FDC. The reluctance of 
clinicians to switch non-treatment naïve ART patients that were considered clinically stable on 
multiple dose regimens to FDC was not justified. The introduction of a fixed dose regimen as part 
of the South African ART Guidelines in December 2012 was a significant step towards improving 
patient adherence to ART treatment. This study also concluded that introduction of the FDC 
regimen did not bridge the adherence gap between females and males. A further investigation was 
needed to determine the effect fixed dose combination regimens have on ART treatment naïve 
patients on clinical outcomes compared to multiple dose regimens and the effect of switching 
non-treatment naïve patients from complex to simpler regimens.  
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After having ascertained that the proportion of patients achieving absolute adherence levels of 
90% were only 65.5% at 6 months and decreasing to 50.9% at 24 months for a 
tenofovir/emtricitabine/ efavirenz based fixed dose combination regimen in chapter 2 a paper 
titled “Impact of Fixed Dose Combination ART drug regimens on Viral Load suppression and 
Clinical Outcomes in a rural setting in South Africa: a retrospective longitudinal study” was 
prepared. The impact of the tenofovir/ emtricitabine and efavirenz based fixed dose 
combination on viral load suppression, immunological response recovery by assessing mean 
C4 count over time, and on clinical outcomes including retention to care and deaths rates was 
evaluated compared to multiple dose regimens and those patients that switched from a multiple 
dose to a fixed dose regimen. A manuscript was prepared following the guidelines of BMC 
Public Health, and presented in Chapter 3 below. 
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Abstract 
Background  
The tenofovir /emtricitabine/efavirenz fixed dose combination (FDC) introduced to improve 
adherence in South Africa in 2013 is only able to achieve at most 65% absolute adherence rates. 
The study aimed to evaluate viral load suppression, immunological response of ART treatment), 
retention to care and death rates as determinants of clinical outcome of ART naïve patients on 
FDC compared to those on multiple dose regimens (MDC).  
Methods  
An institution based, adult patient retrospective pharmacy record review was conducted at four 
facilities rendering ART services of Uthukela District, Kwa-Zulu Natal, initiated from January 
2013 to December 2013. 800 records, with 400 sampled from each of FDC and other MDC 
regimens were selected. A comparison was done between FDC and MDC regimens on Viral load 
(VL) suppression, mean Cd4 count change, retention in care and death rates were determined for 
each group at 6, 12 and 24 months after initiation of ART. Correlation between proportion of days 
covered (PDC) on treatment and VL suppression was evaluated. 
Results 
At 0-6 months 85 patients switched from MDC to FDC, at 12 months 220 had switched, and at 
24 months 252, forming a third group( MDC-unswitched). Overall VL suppression at 6, 12 and 
24 months for FDC was 97%(249/256 tests), 86.2%(145/167) and 89.3%( 191/124) respectively. 
That of MDC-unswitched was 81.8%(23/27), 82%(89/102) and 56%(153/181), p value <0.05 at 
6 and 24 months, and for MDC-switched was 85.5%(23/27); 87.3%(89/102) and 84.5%(153/181) 
p values >0.05 compared to FDC. VL suppression was higher for PDC≥95%. With PDC below 
50% VL suppression for FDC was 93% (31/33), and MDC-unswitched  80% (8/10), p value<0.05 
compared to FDC. VL suppression was positively correlated to PDC at 6 and 12 months with 
FDC, but not at 24 months. The mean Cd4 was higher for MDC than FDC at 12 months, but was 
sustained for FDC at 24 months. A strong negative correlation was found between the female 
gender and vital load suppression for FDC and MDC groups. No positive correlation could be 
found between gender and Mean Cd4 count The retention rate reduced over time for all groups, 
with FDC being 91.2% (363/400 ) at 24 months, 92.5% ( 233/252) for MDC switched p value> 
0.05 compared to FDC, and 81.1% ( 120/ 148) for MDC unswitched, p value < 0.05 compared to 
FDC. At 24 months the death rate for FDC was 4.75% (19/400), that of MDC switched was 1.59% 
(2/252), and for MDC unswitched 17.57% (26/148), p value < 0.05 compared to FDC. 
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Conclusions  
This study demonstrated that overall VL suppression for FDC was higher than MDC unswitched 
regimens at 6 and 24 months, and similar to MDC-switched at 12 and 24 months. FDC 
demonstrated high VL suppression even at low levels of adherence but this could not be 
maintained beyond 6 months. The results suggested that the Tenofivir based FDC demonstrated 
likelihood to higher resistance of viral mutations within the first 6 months of treatment. For 
PDC≥95% patients switched to FDC had VL suppression similar to FDC at 12 and 24 months. 
Immune recovery was sustained better on FDC than MDC. Deaths rates were three times lower 
for FDC than MDC-unswitched. The strong negative correlation was found with female 
adherence and viral load suppression even for FDC, suggests that other factors, other than pill 
load could be contributing to reduced viral load suppression rates for these patients inspite of 
demonstrating higher adherence rates than males. Further research is suggested to evaluate this 
further.  
Keywords: Fixed Dose combination, multiple dose regimens, Viral Load suppression, Mean Cd4 
count, Retention in care, Death rates, South Africa 
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Background 
The Introduction of antiretroviral treatment in SA has resulted in major improved health 
outcomes; however nonadherence to ART treatment still remains a challenge. The strategy of 
introducing a fixed dose combination ART regimen (emtricitabine/ efavirenz/ tenofovir), to 
improve adherence and thus improve viral suppression and clinical outcomes (Davies, 2013) 
needs to be evaluated to determine if gains intended have been achieved. 
The SA government in 2016 introduced a Vision 90-90-90 strategy with the aim of ensuring that 
90% of the infected population knows their HIV status, that 90% of those that tested positive are 
started on treatment; and that 90% of those are virally suppressed. Year to year targets are set 
such that by 2020 this 90-90-90 vision is realised. ‘Treatment as prevention’ is also a core pillar 
of the national HIV/AIDS Strategy, which in turn requires patients to be virally suppressed 
throughout their life time.  
A study conducted by Melaku et al. (2016) in South Africa found that adherence rates to ART 
were 74%, which were lower than the 95% levels of adherence needed to suppress the HIV virus. 
The study also indicated that females had a higher adherence of 80.2% compared to that of males 
which was 69.9%. The HER study in the USA showed that there is direct correlation between 
adherence and viral load suppression. Virologic failure rose with decreasing levels of adherence 
(Stone, 2001). HER study also demonstrated that Factors predicting lower adherence more 
frequent antiretroviral dosing, shorter duration of antiretroviral use, younger age, lower initial 
CD4 lymphocyte count and medication side effects.  Tenofovir/ emtricitabine and efavirenz 
regimen have a potential to cause adverse drug reactions including  compromised sleep quality, 
as efavirenz can cause insomnia and unusual dreams, and tenofovir can cause bone loss and 
kidney function impairment (Hingleyman, 2016 ). These side effects have a potential to reduce 
adherence to treatment. Irregular adherence to ART treatments may result in a definitive loss of 
efficacy of the therapeutic regimen and can lead to the development of resistance to the 
antiretroviral agents that are used (Homar et al. 2012). 
Fixed dose combination antiretroviral therapy have demonstrated efficacy in suppressing HIV 
replication, improve immune function and decrease HIV related morbidity and mortality 
(Armstrong et al. 2015). FDC’s lead to simplification of ART therapy compared with free drug 
regimens, which in turn improves quality of life and adherence to treatment (Masserli, 2007). 
Research conducted in India showed that a fixed dose combination of generic TDF/FTC/EFV was 
effective, and able to achieve viral suppression of 96% at 6 months for ARV –naïve and 
experienced patients (Pujari et al. 2008).  A study by Deeks et al. in 2010 also demonstrated 
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advantage of using fixed dose combination over those regimens with more complex or frequently 
administered regimens.  
A retrospective study conducted at Son Llàtzer Hospital where officials opted to discontinue FDC 
containing emtricitabine, such as AtriplaTM (efavirenz, emtricitabine, and tenofovir), similar to 
one used in SA, in favour of the administration of the separate component drugs , due to lower 
cost of generic lamivudine, indicated that discontinuation of FDC treatment and the replacement 
with the administration of separate antiretroviral agents could lead to an increase in healthcare 
costs due to the higher rate of adverse events that was observed with the discontinuation of FDCs. 
A study conducted in Barcelona found that patients who were virally suppressed and were 
switched to Atripla, were able to be suppressed for 6 months even when skipping doses for a day 
(Martinez et al. 2016). The study also found that taking once-daily Atripla resulted in suppressed 
viral load (below 37 copies/ml) for at least two years, with CD4 count above 350 cells/mm3.  No 
history of virological failure could be found, and no known resistance to efavirenz in this study.  
Disadvantages of fixed drug combinations include reduced flexibility in dosing, exposure of 
patients to drugs that they do not need possible increased risk of adverse side effects, without 
increase in therapeutic benefit (Hennekens, 2008). Fixed dose combinations and once a day 
dosing regimens may also result in higher peaks of drug concentration reached that might result 
in toxic doses reached and increased side effects and adverse reactions of the drugs. These in turn 
if not monitored may reduce the intended improved adherence. 
Multiple-dose regimens were often found to be related non- adherent to treatment, resulting in 
poor clinical outcomes indicated by clinical presentation of Opportunistic Infections whilst on 
treatment and poor virological suppression. (Ajose, 2012).Emtricitabine and lamivudine are 
nucleoside analogue reverse transcriptase inhibitors, similar in structure and antiretroviral 
activity. Studies however suggest that generic single lamivudine may be associated with higher 
rates of M1841/V mutations that could result in viral rebound and treatment failure. The Son 
Llàtzer Hospital study by (Homar et al.2012) however could not find any significant difference 
in virological suppression between those on FDC and those on single drugs. The CP-054 study 
found that patients previously on FDC Atripla (emtricitabine/ efavirenz/ tenofovir) had to be 
changed to FDC (emtricitabine/ rilpivirine/Tenofovir) due to side effects and drug interactions 
related to efavirenz (Chavez, 2015). This has significance as the first line ART regimen treatment 
in SA is Efavirenz based. 
A study comparing adherence and Cd4 count found that adherence levels outperformed CD4 
count changes when used to detect current virologic failure in the first year. CD4 count and 
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adherence could be used in identifying patients at very low risk of virologic failure (Bisson et al. 
2008). A study was conducted at Uthukela district from January to December 2016 to compare 
adherence of a tenofovir/emtricitabine/ efavirenz based fixed dose combination regimen to 
multiple dose regimens. The results of the study suggested that the proportion of patients 
achieving absolute adherence levels of 90% were only 65.5% at 6 months and decreasing to 50.9% 
at 24 months for the fixed dose combination regimen. A further study was then necessary to 
establish effect of fixed dose ART regimen on clinical outcomes, including viral Load 
suppression, immunological response, and mortality, compared to the multiple dose regimens. A 
huge adherence gap previously identified between males and females also needed further 
investigation in terms of clinical outcome to inform practice in the management of patients. 
Methods 
Study Design   
An institution based, comparison retrospective longitudinal study was conducted at 4 Health 
facilities of Uthukela District, Kwa-Zulu Natal. 
Study area and Period 
The study was conducted from January 2016 to December 2017 at four Health facilities that were 
rendering comprehensive ART services. 
Source and study population 
Patient record retrospective reviews of adult patients who were ART naïve on initiation of 
antiretroviral therapy were conducted. The study subjects were initiated on the 1st line treatment 
regimen according the South African ART Treatment guidelines (2013). The study subjects were 
randomly selected from 4 health facilities in the district, stratified to allow one facility from each 
level of care, to include: 1 Regional hospital,1 district hospital, 1 Community Health Centre,  and 
1 Primary health care facility ( randomly selected from the 4 local municipalities that make up 
the district. 
Study subjects were stratified according to the two groups:  
Group 1: Patients initiated on Fixed Dose Combination (FDC) ART regimen; of Tenofovir, 
Emtricitabine and Efavirenz, taken once a day. 
Group 2: Patients initiated on any other multiple- dose ART 1st line regimen. 
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 Inclusion Criteria 
Study subjects were Adult patients (above 18 years of age) who had been on 1st line ARV 
treatment. Only those patients who were ARV naïve on initiation of ART therapy were included 
in the study.  
Exclusion Criteria 
Patients younger than 18 years 
Patients not on antiretroviral therapy 
Patients presenting with any other known comorbid condition on initiation (for an example; TB, 
opportunistic infections, diabetes, and hypertension). 
Patients on 2nd line regimens   
Pregnant women that would have been exposed to the PMTCT programme before initiation on 
HAART. 
Sampling Procedure 
Sampling of Facilities 
Data was collected  from 4 health facilities in the district, one facility at each level of care, to 
include: 1 Regional hospital,1 district hospital, 1 Community Health Centre, and 1 Primary health 
care facility randomly selected from the 4 sub-districts  using stratified random selection from the 
4 local municipalities in the district. 
Procedures for selection of Study Subjects 
Study subjects were patients who started ART therapy in January 2013 to December 2013. The 
subjects were selected from each of the 4 study facilities, and were stratified according to the 
ARV treatment regimen they have been initiated on. Study subjects should have been on 1st line 
ART regimen and should have been on treatment for a minimum period of 3 months, and were 
stratified into two groups as follows:. 
Group 1: Patients on Fixed Dose ARV combination of Tenofovir, Emtricitabine and Efavirenz, 
taken once a day. 
Group 2: Patients on multiple- dose, 1st line ART regimens. 
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Study participants were sampled from a total sample frame of 4357 patients over the same period 
as the FDC group. One patient on the study later found to be younger than 18 years, and was 
excluded from the study, leaving a total sample size of 399 patients.  
Sample Size 
Using a formula by Naing et al, a minimum of 328 participants for each regimen group was 
required to detect at least 10% difference, a power of 80%, and 95% confidence interval. The 
sample size was estimated by using the formula: n = P (1-P) (Z-α/2/E), where P = total number 
of clients on treatment, (Z - α/2) = a constant code representing 95 % of confidence [1.96], E = 
margin of error [+/- 0.05] (Glenn, 1992). An assumption was made to detect at least 10 % (P = 
10%) using the above formula. To accommodate for loss to follow up and drop outs 20% was 
added to the minimum sample size, a maximum of 400 participants per study group was used in 
this study. A total sample size of 400 patients on Fixed Dose regimen and 400 patients on multiple 
dose regimens were included in the final assumption of the sample size. A total Sample size of 
800 participants formed the cohort for the study. This maximum sample size was divided among 
the four facilities included in the study. 100 patients were randomly selected from each of the 4 
facilities for fixed dose combination and multiple dose regimens, respectively, using the formula 
(n+×) based on total number of patients per type of regimen in each facility. For example for 
facility identified as PHC, with 341 patients on multiple dose, the formula n+3 was used for 
selecting 100 clinical chart records 
Data Collection tools and Procedures 
Data was collected using a pretested structured data collection tool administered by 3 trained 
health care workers. The tool was designed to capture the patients file number, ART regimen, 
ART start date, age, gender, and clinical markers Viral load, Cd4 count , laboratory findings, 
presence of opportunistic infections, and clinical outcomes of whether a patient remained on 
treatment, died or was lost to follow up, at baseline, 6,12 and 24 months, as designed in appendix 
8.  Facility held ART Clinical chart records were used to collect clinical information. The data 
from patient ART clinical charts was triangulated with data from an electronic data information 
management system, known as 3–Tier, and with other laboratory records available in the facility. 
Pharmacy refill records were used to identify adherence to diarized drug collections appointment 
dates. 
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To determine Drug Effectiveness Clinical Outcomes were calculated for each of the study groups 
a)  Viral Load suppression as a clinical marker for ART effectiveness was measured at 6 
months, 12 months and at 24 months, for each of the study subjects. Viral load counts of 
less than 400 copies per millilitre of blood, were considered to be suppressed. The Viral 
Load suppression rate was measured for each of the groups at 6 months, 12 months and 
24 months of therapy. 
b) The Mean CD4 count from  was determined, at baseline,  6 months, 12 months and 24 
month for the two groups.  
c) The Proportion of patients Retained in Care was determined, at baseline,  6 months, 12 
months and 24 month  
d) The Death rate was determined at 6 months, 12 months and 24 months for each group 
Data Quality assurance 
Data was collected by using a pre-tested tool by trained health care providers. There was 
continuous supervision to control the data collection procedure. All the data, from each study site, 
was checked by the principal investigator, for completeness, clarity and consistency. The different 
sources of data were used for triangulation. Data was intensively cleaned before analysis.  
Data processing and analysis 
Data was coded and entered into different statistical tools, including Enterprise Miner and SPSS 
windows version 20 for further analysis. Adherence to HAART was assessed by using Proportion 
of days covered (PDC) calculated from using Pharmacy refill records and 3-Tier records. 
Absolute Adherence was measured by working out the number of days covered above 95%. Viral 
Load suppression was analysed by the Health workers and viral load was considered lower than 
suppressed if the viral count was lower than 400 copies per millilitres of blood and/or 
undetectable. 
Bivariate logistic regression was used to check variables associated with the dependent variable. 
Odd ratios with 95% CI were computed and those variables found to have p-values of < 0.05 were 
considered significantly associated with the dependent variable. P values were used to find 
evidence of a significant difference between population means.  
Only those files with available clinical parameters were considered to calculate viral load 
suppression and Mean Cd4 and not the total cohort at baseline. Those patients that had died were 
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also excluded from calculating the viral load suppression rate, however the retention rates and 
death rates were calculated based on the total cohort per regimen. 
Ethical Considerations 
Ethical clearance was obtained from the ethical review Committee of the University of Kwa-Zulu 
Natal. Permission was granted by the Provincial Department of Health. Approval was granted by 
the Uthukela District Director and the CEO’s of the Health facilities, and letters of support were 
provided. Each caregiver and operational manager of the facilities or ART unit was adequately 
informed about the purpose of the study. Patient information was kept confidentially using patient 
codes instead of patient names, and the records were kept in password protected computers.  
Results 
Socio-demographic characteristics of the study subjects 
Two groups of patients, on FDC and MDC, were included in this study. At baseline there were 
400 participants from each group. The majority of the participants in both groups were females; 
with 67.5% (270/400) in the FDC group and 59.3% (237/400) in the MDC group .The median 
age of the FDC group was 33.1 ± 10.3 years while the median age for the MDC group was 32.9 
± 10.1 years. 
A total of 400 prescriptions from the Multiple Dose combination group was comprised of 7 % 
Abacavir based multiple dose regimens, 5.25% Stavudine, 3.25% Zidovudine and 84.5 % 
Tenofovir based.  The second NRTI for all these regimens was Lamivudine, and a third 
component of the HAART regimen was one of the NNRTI’s either Efavirenz or Nevirapine, or 
Protease Inhibitor Lopinavir/ ritonavir.  
Between 0 and 24 months of treatment from the MDC group, a total of 252 participants were 
switched to Fixed Dose Combination regimen and identified as MDC Switched. Multiple Dose 
group was assessed as two distinct sub-groups, those that switched to FDC and those that did not 
switch and remained on MDC. The assessment of adherence was conducted comparing the 3 
groups: FDC, MDC Switched and MDC Unswitched. 
Clinical Marker at baseline of the study subjects 
At baseline, the mean Cd4 count was 181±123.87 cells/ mm3 for FDC (n=356) and 186±127.53 
Cd4 cells/mm3 for MDC (n=337), there was no significant difference between the 2 groups Mean 
Cd4 (p value = 0.623). 
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ARV regimens used by study participants 
At baseline 400 participants on the FDC were started on the 1 TFE Fixed dose combination 
regimens. This only changed at 24 months when 1 participants was changed to a second line 
regimen 2SEL, and one changed to T3N, leaving balance of 398 remaining on FDC ( TFE).   
Table 3.1 presents ART regimen breakdown and profile of participants that were switched, from 
baseline to 24 months, and that of those that remained on the MDC group as unswitched. At 
baseline 80.75% (323/400) of participants on MDC group were on 1 T3E, considered a generic 
equivalent to TFE with Emtricitabine in FDC and Lamivudine in the MDC Group. Between 0 to 
6 months 85 participants were switched to the FDC (TFE), again between 7 to 12 months an 
additional 115 participants were switched to FDC to make a total of 220, and between 13 to 24 
months 32 additional participants were changed from MDC to FDC to make a total of 252.  Most 
of the participants that were switched had been on T3E MDC regimen at baseline. 
Table 3.1: ART regimen breakdown of MDC, MDC Switched and MDC Unswitched group at baseline 
before switch to FDC 
Baseline 0-6 months 7-12 months 13-24 months 
Baseline 
Regimen for 
MDC at 
baseline ( N= 
400) 
Baseline Regimen 
for MDC 
Switched group  
to FDC at 0-6 
months ( N=85) 
Baseline 
Regimen for  
MDC 
Unswitched 
group  at 6 
months             ( 
N=315) 
Baseline Regimen 
for MDC Switched 
group  to FDC at 
7-12 months ( 
N=220) 
Baseline Regimen 
for MDC 
Unswitched group  
at 12 months                     
( N=180) 
Baseline Regimen 
for MDC Switched 
group to FDC at 
13-24 months ( 
N=252) 
Baseline Regimen 
for MDC 
Unswitched group 
at 24 months          
     ( N=148) 
1A3E= 6.75% 
(n=27) 
1 S3E= 2.35%( 
n=2) 
1 A3E= 8.57% ( 
n=27) 
1 A3E= 3.18% 
(n=7) 
1A3E= 11.11% 
(n=20) 
1A3E= 3.17%( 
n=8) 
1A3E= 12.84%  
( n=19) 
1A3N= 0.25% 
(n=1) 
1 T3E= 85.88% 
(n=73) 
1A3N=0.32% 
(n=1) 
1S3E=3.18% 
(n=7) 
1 A3N= 0.56% 
(n=1) 
1S3E= 3.17% ( 
n=8) 
1A3N= 0.67%  
( n=1) 
1S3E= 4.75% 
(n=19) 
1 T3N= 3.53% 
(n=3) 
1S3E=5.4% 
(n=17) 
1T3E= 88.6% 
(n=195) 
1S3E= 6.67% ( 
n=12) 
1T3E= 89.3%  
( n=225) 
1S3E= 7.43% 
(n=11) 
1S3L= 0.25% 
(n=1) 
1 Z3E= 8.24% 
(n=7) 
1S3L= 0.32% 
(n=1) 
1TFN= 1.82% 
(n=4) 
1 S3L = 0.56% 
(n=1) 
1T3N= 1.59% 
(n=4) 
1S3L= 0.67% (n=1) 
1S3N= 0.25% 
(n=1) 
  
1S3N= 0.32% 
(n=1) 
1Z3E=3.18% ( 
n=7) 
1 S3N= 0.56% 
(n=1) 
1Z3E= 2.78% ( 
n=7) 
1S3N- 0.67% (n=1) 
1T3E= 80.75% 
(n=323) 
1T3E=79.4% 
(n=250) 
  
1T3E= 71.1% 
(n=128) 
  
1T3E= 66.22% 
(n=98) 
1T3L= 0.25%  
( n=1) 
1T3L= 0.32% 
(n=1) 
1T3L= 0.56% (n=1) 
1T3L= 0.67% ( 
n=1) 
1T3N= 3.5%  
( n=14) 
1T3N= 3.5% 
(n=11) 
1T3N =5.56% 
(n=10) 
1T3N= 6.78%  
( n=10) 
1Z3E= 3.25% 
 ( n=13) 
1Z3E= 1.9% 
(n=6) 
1Z3E = 3.33% ( 
n=6) 
1Z3E = 4.05%  
( n=6) 
Legend: 3= Lamivudine, A= Abacavir, E= Efavirenz, F= Emtricitabine, L= Lopinavir, Ritonavir comb, N= Nevirapine, S= Stavudine, T= Tenofovir, Z= 
Zidovudine, FDC= Fixed Dose Combination of Tenofovir/Emtricitabine and Efavirenz. MDC= Multiple Dose Combination 
Comparison of Viral Load Suppression between FDC, MDC switched and MDC unswitched 
Table 3.2 presents differences in the Proportion of study participants who had Viral Load 
Suppression at month 6, 12, and 24 between FDC, MDC witched and MDC unswitched.  
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VL suppression at 6 months for FDC was 97% (249/256), that of MDC switched 85% (23/27) at 
6 months, p value < 0.05. At 12 months VL suppression for FDC was 86.8% (145/167) higher 
than that of MDC Unswitched that was 81.8% (72/88), p value < 0.05. MDC switched at 12 
months was 87% (89/102) not statistically different to FDC, p value> 0.05.There was a 
progressive decline in VL suppression for MDC unswitched to 56.7% (17/30), but for FDC and 
MDC switched groups VL suppression remained high at 89.3% ( 191/214) and 84.5% ( 153/181) 
respectively, p value > 0,05.  
Table 3.2 suggests that over time, for FDC, viral load suppression was maintained at levels above 
80% at 6, 12 and 24 months, surpassing both MDC switched and MDC unswitched. MDC 
switched VL suppression almost remained a constant with a slight decline at 24 months. At 12 
months there was no significant difference between VL suppression for FDC and MDC switched. 
At 24 months VL suppression declined drastically for MDC switched. 
Table 3.2:  Viral Load Suppression for FDC, MDC switched and MDC unswitched over time 
Legend: No= number of tests done, VL suppr = Viral Load Suppression, NR= not recorded. 
Adherence and Viral Load Suppression 
Figure 3.1 represents the relationship of PDC with viral load suppression for FDC, MDC switched 
and MDC unswitched at 6, 12 and 24 months. MDC had a relatively higher PDC than FDC and 
MDC switched, but FDC had a higher proportion of participants that were virally suppressed. The 
FDC group achieved a 97% viral suppression at 6 months in spite of adherence rates of 65,5%, 
but thereafter at 12 months VL suppression was to 86.8% with adherence rates of 59% , to recover 
again at 24 months to 89% with adherence rates of 50.9%. At 6 months, viral suppression was 
almost similar with all the groups, in spite of MDC switched having a larger proportion of days 
covered on treatment. 
DUR
No. VL 
taken
VL Suppr NR 95%CI
No. VL 
taken
VL Suppr NR 95%CI p value
No. VL 
taken
VL Suppr NR 95%CI p value
6 256
97.26%         
( n=249)
121  94.47-98.67 27
85.2% ( 
n=23)
57  46.1-75.93 <0.0001    88
81.8% 
(n=72)
204  72.49-88.49 <0.0001
12 167
86.8%          
( n=145)
208  80.86-91.14 102
87.3% 
(n=89)
116  79.4-92.39  0.92034 37
82.2% 
(n=37)
109  68.67-90.7
0.42952
24 214
89.3% 
(n=191)
157  84.39-92.73 181
84.5% 
(n=153)
65  78.55-89.07
0.16452
30
56.7% 
(n=17)
90
 39.2-72.63
 <0.0001
 FDC  MDC Switched MDC UNSwitched 
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Figure 3.1: PDC and Viral load suppression over time, with FDC, MDC and MDC 
unswitched. 
 
Viral load suppression at levels of adherence above ≥ 95% 
Table 3.3 presents a comparison of Viral load for the participants on the three regimens at varying 
levels of adherence to treatment. At 6 months for patients who had PDC ≥ 95%, VL suppression 
for FDC was 98.3% (171 out of 174 tests) , for MDC switched it was 86.9% (20 out of 23 tests)  
and for MDC unswitched it was 81.4% ( 57 out of 70 tests). The difference in VL suppression 
between FDC and MDC switched, and between FDC and MDC unswitched was significant, with 
FDC demonstrating higher VL suppression, p value < 0.05. At 12 months there was no significant 
difference in VL suppression rates between FDC and the two other groups, p value > 0.05. At 24 
months, there was no significant difference between VL suppression for FDC and MDC Switched. 
The difference in VL suppression was significant between FDC where VL suppressions was 
92.4% (133 VL suppressed out of 144) and was 63.2% (12 VL suppressed out of 19) for MDC, p 
value < 0.05.At PDC≥95% at 6, 12 and 24 months Viral load suppression ranged between 89%-
98% for FDC,  remained constant at 87% for MDC switched, and VL suppression dropped from 
81% at 6months, to 77% at 12 months and further to 6% at 24 months. 
Viral load suppression at levels of adherence below (PDC < 50%) 
For those participants that had PDC below 50% at 6 months, VL suppression for FDC was 93% 
(31/33),  MDC-switched 50%(23/27) and MDC-unswitched  81.8%(72/88). The difference in VL 
suppression was significant between FDC and MDC switched (p value < 0.05) but not between 
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FDC and MDC unswitched (p value > 0.05). At 12 months VL suppression for FDC was lower 
than that of MDC switched (56.5% versus 76.9%) which in turn was also lower than that of MDC 
unswitched (95.5%), however the difference was only significant between FDC and MDC 
unswitched groups. At 24 months there was no statistically significant difference between VL 
suppression between FDC (76.6%) and MDC switched (88.9%) and between FDC and MDC 
unswitched (71.4%).  
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PDC
No.VL 
taken
% VL 
Suppr
Not 
Rec
95%CI
No.VL 
taken
% VL 
Suppr
Not 
Rec
95% CI p value
No.VL 
taken
% VL 
Suppr
Not 
Rec
95% CI p value
174 98.3% 73 23 86.9% 39 0.003 70 81.4% 119 <0.0001
(n=247) n=171 (n=62) n=20 (n=189) n=57
14 85.7% 7 0 2 3 100.0% 3 0.4839
(n=21) n=12 (n=2) n=0 (n=6) n=3
32 100% 3 1 100% 12 <0.0001 5 80% 6 0.1046
(n=35) n=32 (n=13) n=1 (n=11) n=4
3 100% 3 1 100% 0 <0.001 0 1
(n=6) n=3 (n=1) n-1 (n=1)
33 93.3% 35 2 50% 4 <0.0001 10 80% 75 0.1835
(n=68) n=31 (n=16) n=1 (n=85) n=8
N 256
97.26% 
(n=249)
121 94.47-98.67 27
85.2% 
(n=23)
57 46.1-75.93 0.002 88
81.8% 
(n=72)
204 72.49-88.49
<0.0001
T/O 1.5% (n=6) 1.18% (n=1) 0.8181 0.95% (n=3) 0.8572
Died 4.25% % (n=17) 0% (n=0) 0.0536 6.35% (n=20) 0.0173
Total 400 85 315
PDC
No.VL 
taken
% VL 
Suppr
Not 
Rec
95%CI
No.VL 
taken
% VL 
Suppr
Not 
Rec
95% CI p value
No.VL 
taken
% VL 
Suppr
Not 
Rec
95% CI p value
121 89.3% 101 77 87.0% 82 0.6312 18 77.7% 38 0.1645
(n=222) n=108 (n=159) n=67 (n=56) n=14
15 100% 7 2 100% 5 <0.0001 1 0% 0 <0.0001
(n=22) n=15 (n=7) n=2 (n=1) n=0
13 84.6% 20 9 100% 6 0.2187 4 50% 2 0.1527
(n=33) n=11 (n=15) n=9 (n=6) n=2
3 66.6% 2 1 100% 1 0.5029 0 1
(n=5) n=2 (n=2) n=1 (n=1)
16 56.3% 78 13 76.9% 22 0.246 22 95.5% 68 0.0034
(n=94) n=9 (n=35) n=10 (n=90) n=21
N 167
86.3% 
(n=145)
208 80.86-91.14 102
87.3% 
(n=89)
116 79.4-92.39 0.9203 37
82.2% 
(n=37)
109 68.67-90.7
0.4295
T/O 1.5%(n=6) 0.69-3.23 0.91% (n=2) 0.25-3.25 0.5353 1.11% (n=2) 0.7114
Died 4.5% (n=18) 2.87-7.00 0% ( n=0) 0.0-1.72 0.0014 13.33% (n=24) 0.0001
Total 400 220 180
PDC
No.VL 
taken
% VL 
Suppr
Not 
Rec
95%CI
No.VL 
taken
% VL 
Suppr
Not 
Rec
95% CI p value
No.VL 
taken
% VL 
Suppr
Not 
Rec
95% CI p value
144 92.4% 45 147 86.4% 28 0.0989 19 63.2% 9 0.0001
(n=189) n=133 (n=175) n=127 (n=28) n=12
11 81.8% 9 6 50% 0 0.1676 2 0% 0 0.0209
(n=20) n=9 (n=6) n=3 (n=2) n=0
28 89.3% 7 9 66.7% 1 0.1096 1 0% 0 0.0111
(n=35) n=25 (n=10) n=6 (n=1) n=0
1 100.0% 3 1 100.0% 1 <0.0001 1 0% 0 0.1585
(n=4) n=1 (n=2) n=1 (n=1)
30 76.7% 93 18 88.9% 35 0.2937 7 71.4% 81 0.7718
(n=123) n=23 (n=53) n=16 (n=88) n=5
N 214
89.3% 
(n=191)
157 84.39-92.73 181
84.5% 
(n=153)
65 78.55-89.07 0.1645 30
56.7% 
(n=17)
90 39.2-72.63
<0.0001
T/O 2.0% ( n=8) 1.02-3.92 1.59% (n=4) 0.62-4.01 0.6965 1.35% (n=2) 0.37-4.79 0.5892
Died 4.75% (n=19) 3.07-7.33 1% (n=2) 0.22-2.84 0.0051 17.57% (n=26) 12.28-24.50 <0.0001
Total 400 252 148
Legend: PDC= Proportion of days covered,  FDC= Fixed Dose Combination regimen, MDC = Multiple dose combination regimen, % VL suppr= 
Percentage Viral Load Suppressed, Not Rec= Not recorded
Table 3.3: Comparison between level of adherence and Viral Load suppression 
 FDC  MDC Switched  MDC Unswitched
 MDC UnswitchedMDC Switched  FDC  
<50%
59.08-
88.21
67.2-96.90 35.89-91.78
6 months
12 months
24 months
65-79%
72.81-
96.29
35.42-87.94 0-79.35
50-64% 20.65-100 20.65-100 0-79.35
≥95%
86.84-
95.68
79.91-91.01 41.04-80.85
80-94% 52.3-94.86 18.76-81.24 0-65.76
50-64%
20.77-
93.85
20.65-100
<50% 33.18-76.9 49.74-91.82 78.2-99.19
80-94% 79.61-100 34.24-100 0-79.35
65-79%
57.77-
95.78
70.09-100 15-85.0
<50%
80.39-
98.32
1.49-35.38 49.02-94.33
≥95%
82.49-
93.62
77.71-92.79 54.79-91
 FDC  MDC Switched  MDC Unswitched
65-79% 89.28-100 20.65-100 37.55-96.38
50-64% 43.85-100 20.65-100
≥95%
95.06-
99.41
67.88-95.46 70.78-88.81
80-94%
60.05-
95.99
43.85-100
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Differences in PDC and Viral load Suppression between females and males in the FDC 
group 
The results from table 3.4 present a comparison of PDC and viral load suppression between 
females and males for FDC. The results suggest that Females had higher Viral load suppression 
than males for FDC, at 6 months (97% vs 89.16%), this difference was only statistically 
significant, p values< 0.05.  At 12 and 24 months males demonstrated a higher viral load 
suppression rate than females (83.05% versus 80%, and 83.05% vs 80% respectively), however 
this difference was not statistically significant, p value > 0.05. 
Table 3.4: Differences in PDC and viral load suppression between females and males on FDC 
 
         Legend: FDC= Fixed Dose combination regimen 
Comparison in Cd4 count between FDC, MDC switched and MDC unswitched over time 
Table 3.5 presents the mean differences in Mean CD4 count (cells per mm3 of blood) of study 
participants at month 6, 12, and 24 between FDC and MDC 
At Baseline 356 out of 400 participants had CD4 tests done for FDC and the mean CD4 count 
was 181.54 cells/ mm3. For MDC 337 out of 400 participants had CD4 tests done and the mean 
CD4 count was 186.24 cells/ mm3 of blood. The results suggest that there was no Immunological 
difference in the two groups at baseline, p value < 0.05. At 6 months the difference in mean CD4 
count was significant between FDC and MDC switched with MDC switched demonstrating lower 
mean Cd4 count. At 12 months there was a significant difference between FDC and MDC 
unswitched, with MDC switched having higher Mean Cd4 count. 
At 6 months the mean Cd4 count for FDC was 319.8 cells/mm3 ( 28% increase) , at 12 months it 
was 404.83 cells/mm3  ( 28% increase) and at 24 months it was 457.29 cells/mm3 ( 26.6%).  At 
12 months there was a 123% recovery in Cd4 count from baseline. At 24 months, there was an 
overall 152.9% recovery from baseline. For MDC unswitched at 6 months there was an increase 
Females Males p-value
No of VL 
tests 
Females
Females 
Suppressed
%, with 
95%CI
No of VL 
tests Males
Males 
Suppressed
%, with 
95%CI
p-value
6 months
68±29.25 
(n=259)
62±32.24 
(n=118)
0.9353 178 97% (n=173) 93.59-98.79 83
89.16% 
(n=74)
80.66-94.99 0.007*
12 months
64±32.40 
(n=259)
53±37.25 
(n=117)
0.0068* 132
78.78% 
(n=104)
71.05-84.90 39
87.18 % 
(n=34)
73.29-94.40 0.242
24 months
57 ± 35.14 
(n=256) 
46 ± 39.87 
(n=115) 
0.0067* 165 80% (n=132) 73.25-85.39 59
83.05% 
(n=49)
71.54-90.52 0.61
Duration on
Treatment 
Proportion of Viral load suppression on FDC
Means of PDC with FDC ( out of 84
days)
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of 51% from baseline, 168% at 12 months from baseline ( 78% increase from 6 months) and at 
24 months Cd4 count dropped by 16%. For MDC switched Cd4 count recovered at 12 months by 
100% from 6 months, however at 24 months this dropped by 13% 
Table 3.5: Change in Cd4 cell count over time 
 
 Mean CD4 
count for  
FDC            
(cells/mm3) 
 Mean Cd4 
count for  MDC 
Switched          ( 
cells/mm3) 
p value 
Mean CD4 
count for MDC 
Unswitched        
( cells/mm3) 
*p value **P value 
Baseline 181.54±123.87 N/A    186.24±127.53 *0.623   
6 months 319.80±219.47 230 ± 153.33 *0.003144 280 ± 210.47 *0.135179 **0.71995 
12 
months 404.83±226.46 460.40±353.808 *0.178153 
498.56±252.955 
*0.000261 **0.414235 
24 
months 457.24±246.27 402.909±219.38 *0.182169 420.82±239.92 
*0.175433 
**0.657225 
Legend: PDC=proportion of days covered, FDC=fixed dose combination, MDC=multiple dose combination. * statistical significance 
when compared to FDC. ** Statistical significance when comparing MDC switched to MDC Unswitched 
Correlation between Gender, Absolute Adherence, Viral Load and Cd4 count at 6, 12 and 
24 months 
Table 3.6 presents correlation between Gender, Absolute adherence and viral load using Pearsons  
p value. The results suggest that there was negative correlation between adherence and gender at 
6, 12 and 24 month, however, the results were not statistically significant. The results suggest that 
there was a strong negative significant correlation between gender and Viral Load suppression at 
12 months and 24 months, but the negative correlation at 6 months was insignificant. There is 
strong significant positive correlation between Adherence and VL Load Suppression at 6 months 
and 12 months however though correlation is positive at 24 months this was not statistically 
significant. 
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Table 3.6: Correlation between Gender, Absolute adherence and viral load count over time 
  Adherence Viral load Suppression 
 
  
FDC 
6mths 
FDC 
12mths 
FDC 
24mths 
MDC 
6mths 
MDC 
12mths 
MD
C 
24mt
hs 
FDC 
Suppr 
6mths 
FDC 
Suppr 
12mths 
FDC 
Suppr 
24mth
s 
MDC 
Suppr 
6mths 
MDC 
Suppr 
12mths 
MDC 
Suppr 
24mths 
G
en
d
er
 
Gender 
FDC 
-0.076 -0.025 -0.061 0.011 0.033 0.02 -0.03 -.170** 
-
.129** 
-0.042 0.052 0.009 
Gender 
MDC  
-0.004 -0.004 -0.016 0.034 0.052 
0.08
6 
-0.008 -0.037 0.001 -0.007 0.034 -0.028 
A
d
h
er
en
ce
 
FDC 
6mths 
  .852** .778** -0.042 0.016 
0.04
4 
.262** .293** 0.087 .103* 0.067 0.066 
FDC 
12mths 
    .791** -0.026 0.007 
0.04
7 
.261** .225** 0.059 .123* 0.088 0.052 
FDC 
24mths 
      -0.055 -0.011 0 .233** .226** 0.061 0.09 0.072 0.057 
V
ir
al
 l
o
ad
 
S
u
p
p
re
ss
io
n
 
MDC 
6mths 
        .802** 
.740*
* 
.226** .122* 0.083 0.084 0.029 -0.063 
MDC 
12mths 
          
.856*
* 
.189** 0.047 0.046 .157** 0.098 -0.042 
MDC 
24mths 
            .200** 0.097 0.045 .105* 0.07 -0.066 
Legend
 :        
*. Correlation is significant at the 0.05 level (2-tailed). 
 
 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
PDC=proportion of days covered, FDC=fixed dose combination, MDC=multiple dose combination.  
 
Retention to care 
Table 7 presents retention in care and overall clinical outcomes over time for FDC, MDC switched 
and MDC unswitched. At 6 months out of the 400 participants in the FDC group, 368 (92%) were 
retained in care, 9 (2.25%) were lost to follow, 6 transferred out and 17 (4.25%) participants died. 
From MDC switched, of the 85 participants that were switched to FDC at the end of 6 months, 84 
(98%) were retained on treatment and 1 was transferred out. From the 315 that remained on MDC 
unswitched 279 were retained on treatment, 13 (4.12%) were lost to follow up, 3 transferred out 
and 20 (6.3%) participants died. At 12 months duration on treatment, retention in care rate reduced 
to 91.8% for FDC, 04.5% for MDC switched and 83, .9% for MDC unswitched. At the end of the 
24 month period, 2 patients from FDC were switched to a second line multiple dose regimen, 
leaving a total sample of 398. Of the 400 on FDC 363 (90.75. %) were retained, 8 (2%) were lost 
to follow up, 8 (2%) were transferred out and 19 (4.8%) died. From the original 400 participants 
on MDC, a total of 252 were switched at the end of 24 months to FDC, of those 233 (92.5%) were 
retained, 13 (3.15%) were lost to follow up, 4(1.58%) were transferred out, and 3 died (0.79%). 
Of the 148 that remained on MDC, 120 (81.1%) were retained, 2 (transferred out), and 26 (17.6%) 
participants died. 
Death rates of FDC, MDC switched and MDC unswitched at 6, 12 and 24 months 
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Table 3.7 also presents death rates at month 6, 12, and 24 between FDC, MDC witched and MDC 
unswitched.  
The death rate at 6 months for FDC was 4.25% (17/400), that of MDC switched 0% (0/85), and 
MDC unswitched 6.35% (20/315), with p value < 0.05 between FDC and MDC unswitched. 
Difference in death rates for MDC switched at 6 months was not statistically different to FDC, p 
value > 0.05. At 12 months the Death rate for FDC was 4.5% (18/400), for MDC Unswitched it 
was retained at 0% (0/220), and for MDC unswitched was 13.33% (24/180). At 24 months the 
death rate for FDC was 4.75% (19/400), that of MDC switched being the lowest at 1.59% (2/252), 
p value< 0.05, and for MDC unswitched 17.57% (6/148), p value < 0.05 compared to FDC. 
There was a progressive increase in death rates for FDC and MDC unswitched from 6, 12 to 24 
months, and from 12 to 24 months for MDC switched.  The results suggest that there were 
significantly higher deaths rates for MDC unswitched than FDC, p value < 0.05, at 6, 12 and 24 
months. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.7: Retention to care and death rates over time 
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6 MONTHS 
  
FDC    
(n,%) 
95%CI 
MDC 
Switched 
(n,%)  
95%CI P value 
 MDC 
Unswitched 
(n,%) 
95%CI P value 
Retained 
 368            
92% 
88.92-
94.28 
84           
98.8% 
93.63-
99.79 
0.0232 279    88.6% 
84.58-
91.63 
0.00374 
LTF 
9 1.19-4.22 0 0-4.32 0.16152 13 2.43-6.94 0.05744 
2.25%   0%     4.12%    
T/O 
6 0.69-3.23 1 0.21-6.37 0.8181 3 0.32-2.76 0.85716 
1.50%   1.18%     0.95%     
Died 
17 2.67-6.7 0 0-4.32 0.0536 20 4.15-9.6 0.01732 
4.25%   0%     6.30%     
Total N=400   N=85     N=315     
12 MONTHS 
  
FDC    
(n,%) 
95% CI 
MDC 
Switched 
(n,%)  
95% CI P value 
 MDC 
Unswitched 
(n,%) 
95%CI P value 
Retained 
367      
91.8% 
88.92-
94.28 
208       
94.5% 
90.71-
96.86 
0.20054 151      83.9% 
77.82-
88.54 
0.00466 
LTF 
9 1.19-4.22 10 2.49-8.17 0.11184 3 0.57-4.79 0.64552 
2.25%   4.54%     1.67%     
T/O 
6 0.69-3.23 2 0.25-3.25 0.53526 2 0.3-3.96 0.71138 
1.50%   0.90%     12.20%     
Died 
18 2.67-6.7 0 0-1.72 0.00142 24 9.12-19.07 0.00014 
4.50%   0%     13.33%     
Total N=400   N=220     N=180     
24 MONTHS 
  
FDC   
(n,%) 
95% CI 
MDC 
Switched 
(n,%)  
95% CI P value 
 MDC 
Unswitched 
(n,%) 
95% CI P value 
Retained 
363         
91.2% 
88.02-
93.61 
233    
92.5% 
88.52-
95.12 
0.57548 
120         
81.1%  
74.01-
86.57 
0.001 
LTF 
8 1.02-3.92 13 3.04-8.36 0.0271 0 0-2.53 0.08186 
2%   5.16%     o%     
T/O 
8 1.02-3.92 4 0.62-4.01 0.69654 2 0.37-4.79 0.61006 
2%   1.58%     1.35%     
Died 
19 2.88-7.03 2 0.22-2.84 0.00512 26 12.28-24.5 <0.0001 
4.75%   0.79%     17.60%     
Total 400   252     148     
Legend: PDC=proportion of days covered, FDC=fixed dose combination, MDC=multiple dose combination. T/O= Transfer out, LTF= 
Lost to follow up 
Discussion 
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The study sought to find the effect of reduced pill load and regimen complexity on immunological 
response and clinical outcomes including retention to care. Participants on a Tenofovir based 
fixed dose combination were monitored for viral load suppression and Cd4 count recovery against 
those that were started on multiple dose regimens, and against those that were initially on a 
multiple dose regimen but later switched to the same fixed dose regimen, forming a third group 
from which the effect of switch to a fixed dose combination was reported on. Levels of adherence 
to the three regimens, FDC, MDC switched and MDC unswitched were compared over time, at 6 
months, 12 months and 24 months on treatment, and the effect that had on immunological 
response. The difference in response between FDC and the two other groups was evaluated to 
determine the effect of fixed dose combination regimen. Viral load suppression was regarded as 
participant’s viral load below 400 copies per mm3 of blood. 
The findings of this study suggest that even though the proportion of days covered for FDC was 
below the optimum level of absolute adherence of 95%, ranging from 78% at 6 months, 71% at 
12 months and declining further to 64% at 24 months, the viral load suppression rate remained 
high, being 97% at 6 months, 87% at 12 months and 89% at 24 months. With PDC below 50%, 
VL suppression rates for FDC at 6 months were 93% at 6 months, but declined to 53% at 12 
months, and recovered to 74% at 24 months. These findings seem to be in support of Martinez’ 
et al. findings that even when skipping doses to three times a week on Atripla, viral load 
suppression can be maintained for 24 weeks (Martinez et al. 2016). This indicates the potency of 
the regimen in spite of reduced adherence. In this study, however, VL suppression rates were only 
53% at 12 months, and one patient was switched to second line regimen due to treatment failure 
contrary to Martinez et al study which found no virological failure at 24 months for patients on 
the daily dose of Atripla. 
In this study there was a strong positive correlation found between proportion of days covered on 
treatment and VL suppression at 6 and 12 months, but there was no significant correlation at 24 
months. This was partly in agreement with Stone (2001) who stated that as adherence increased, 
viral load suppression also increased. The limited correlation with high VL suppression in spite 
of lower adherence at 24 months, could be a confirmation of emergence of viral mutations over 
time, but VL suppression for FDC was still better than multiple dose regimens; this is in 
agreement with a study by Homar (2012), where lamivudine based regimen showed quicker 
mutations than its equivalent emtricitabine.  
Findings in this study indicated that mean PDC for FDC was significantly higher than that of 
MDC unswitched at 6, 12 and 24 months. Subsequently viral load suppression was higher for 
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FDC than the MDC unswitched group at all three intervals of duration on treatment; however the 
difference in viral load suppression was not significant at 12 months. When also observing the 
proportion of participants with PDC ≥ 95% viral load suppression was higher for FDC though not 
significant at 12 months. There was strong positive correlation with MDC unswitched between 
PDC and viral Load suppression. As PDC reduced, so did viral suppression. A study conducted 
in Mozambique confirmed the linear correlation between adherence and viral load suppression 
(San Lio et al., 2008).  
When comparing MDC unswitched in this study, the switched patients had better adherence and 
demonstrated higher viral suppression rates than MDC unswitched. These findings indicate the 
positive effect of switching even non-treatment naïve patients to FDC. These results were in 
agreement with the Armstrong et al. study conducted in Australia which found that when patients 
switched from multiple dose regimens to a fixed dose single pill regimen, adherence improved 
and viral suppression rates improved better than MDC regimens (Armstrong et al., 2015). 
When compared to FDC in this study, the MDC switched group had much higher PDC values 
than FDC; however, the viral load suppression was surpassed by that of FDC at 6 months, while 
it remained similar to that of FDC at 12 and 24 months. This again indicated the positive effect 
FDC switches have on adherence and viral load suppression in non-treatment naïve patients 
(Armstrong et al., 2015). The difference in viral load suppression at 6 months could be related to 
the duration of the period to which the participants were on FDC as well as on the clinical profile 
of the participants. When observing the Cd4 count at 6 months, the MDC switched had a 
significantly lower mean Cd4 count than that of FDC, compromising VL suppression in spite of 
good adherence at 6 months.   
This study found that there was a gender difference in PDC within the FDC group and not  within 
MDC switched and MDC unswitched groups, with females demonstrating higher PDC at 6, 12 
and 24 months than males, though not significant at 6 months; however this difference did not 
translate to improved viral load suppression for females. Females had a significantly higher viral 
load suppression rate than males at 6 months, but males had higher viral load suppression rates at 
12 and 24 months, however this was only significant at 6 months. There was a strong negative 
correlation between gender and viral load suppression. A study in India could not find correlation 
with gender and adherence and gender and viral suppression (Shah et al. 2007). The findings in 
this study at 6 months, agreed with findings in a Uganda study where viral load suppression was 
associated with the female gender (Kipp et al. 2010), however this was not applicable at 12 and 
24 months.  
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Immunological response in this study indicated by Cd4 count recovery from baseline,  improved 
by more than 100% , for all the study groups, in line with expected standards of doubling the Cd4 
counts after 12 months of therapy ( Management of HIV/Aids, 2015). The Cd4 recovery rate was 
higher for MDC unswitched group than FDC at 6 and 12 months, however at 24 months Cd4 
declined for MDC unswitched but remained on an up cline for FDC. The difference in mean Cd4 
values at 24 months was insignificant. The increase in CD4 count for MDC unswitched could not 
be associated with improving VL suppression. A study in India by Pozniak et al (2006) showed 
that a Zidovudine fixed dose combination had a significant lower increase in Cd4 count than a 
multiple dose regimen and that a fixed dose combination does not necessarily result in improved 
clinical outcomes; the regimen make-up also contributes to clinical outcomes. In this study FDC 
VL suppression rates were better maintained with improving CD4 count.  FDC immunological 
response was more in line with expected results. A study conducted in San Francisco, found that 
Mean VL copies were highest among the groups of people with the lowest CD4 counts, linearly 
decreasing as CD4 count increased (Das et al. 2010). A study by Bisson et al. (2008) indicated 
that Cd4 count recovery is a good predictor of viral suppression failure, and this could be related 
to lower viral suppression rates on MDC clients at 24 months.  
Overall retention in care rate for FDC in this study was significantly higher than the MDC 
unswitched at 6, 12 and 24 months, but it was not different to that of MDC switched at 6 months. 
At 12 and 24 months the switched group had even higher retentions rates than FDC. This shows 
the effect of fixed dose combination on retention with the benefit of switching from multiple doses 
to fixed dose combination demonstrated. These results were in agreement with the Armstrong et 
al. study conducted in Australia which found that when patients switched from multiple dose 
regimens to a fixed dose single pill regimen, adherence improved better than MDC regimens 
(Armstrong et al., 2015). Contrary, a study conducted by Hirasen et al., in Johannesburg, South 
Africa found no significant difference in attrition rates between FDC and MDC at 12 months 
(Hirasen et al., 2017).  
Death rates were significantly higher for the MDC unswitched group than FDC at 6, 12 and 24 
months, with the biggest difference at 24 months (17.6% versus 4.77%). Lost to follow up where 
highest with the MDC unswitched group at 6 months but were higher with FDC at 12 months and 
with MDC switched at 24 months.   
 
Strengths and limitations of the study  
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Viral load tests were not completed by clinicians timeously for all the patients retained to care 
according to prescribed treatment protocols. The viral load test and Cd4 count completion rates 
were lower than optimal ranging between 46 and 64%. The recording of the results on patients’ 
clinical charts was also poor, but attempts were made to triangulate data from laboratory records. 
No other clinical files were kept in the facility. Medical information was held in patient held 
records that they took home. This was a gap identified with the Health patient record management 
systems. 
Conclusion 
The findings of this study showed that the fixed dose combination demonstrated better adherence 
at 12 and 24 months compared to multiple dose regimens. FDC demonstrated better viral 
suppression than multiple dose regimens at 6, 12 and 24 months. Viral load suppression for FDC 
was maintained at high levels close to 90% even by those patients that had less than 50% 
proportions of days covered on treatment, at 6 months, however VL suppression declined 
thereafter with these poor adherers. The impact of switching non-naïve patients from multiple to 
fixed dosed regimens had a positive effect on viral load suppression and on adherence. Even 
though the multiple dose regimen patients demonstrated higher Cd4 count recovery than FDC at 
12 months, this could not be maintained at 24 months, whereas with FDC Cd4 counts continued 
to improve. In this study females on FDC demonstrated better adherence rates than males, but this 
only translated to better viral load suppression rates at 6 months. Significantly more patients were 
retained on the fixed dose combination than multiple dose regimens. 
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4. 1 Impact of FDC on adherence 
Only a few years are left before all countries are to meet the Vision 90-90-90 targets and yet only 
a few countries have achieved those, and South Africa is not there yet. According to Marconi V, 
2013, South Africa is reporting low levels of virologic failure but the challenge is to maintain 
those low levels. It therefore remains critical that patients must remain virally suppressed and as 
many factors contribute to non-adherence, the introduction of fixed dose regimen is only bit one 
of the strategies of improving adherence. The results from the first study indicated that better 
adherence was achieved with the fixed dose combination compared to those of multiple dose 
regimens but the levels of 65% of absolute adherence at 6 months are far from being optimal. At 
24 months absolute adherence for FDC was 50% and that of MDC was 23.3%. The adherence 
curve theory by Friedland states that at around 21 weeks a patients motivation to taking their 
medication plateaus, this study is in agreement with that theory as soon after 6 months the 
adherence levels dropped, even for these patients that need to be on ART for life.  
The FDC was not able to bridge the differences in adherence between females and males. Of 
interest findings from his study indicated that females had the lowest adherence rates on MDC 
unswitched regimen than males at 6 months contrary to previous studies conducted in SA ( 
Melaku et al., 2016)  and in India (Shah et al., 2007). With FDC females demonstrated better 
adherence than males. This suggests that females may be more compromised than males in taking 
more complex regimens, especially early on in treatment. This needs further investigation. 
Marconi in 2013 also noted this phenomenon where females did not do well as expected, where 
he identified that women experienced more ARV related adverse drug reactions (ADR’s) than 
males. This study’s limitation was that it was not able to evaluate the impact of FDC on reducing 
drug toxicities, due to the fact that recording of clinical notes on patients charts was not optimal. 
This factor on its own could also indicate that side effects on FDC and on MDC might not have 
been properly managed if not documented. Side effects and ADR’s contribute to non-adherence 
to treatment even on FDC (Pujari,2008, and Chavez, 2015). Other strategies other than regimen 
simplication have to be adopted to maintain optimal viral suppression. Strategies to address 
socioeconomic factors, access to health facilities, health system factors,  gender adherence gaps 
all will have an impact on improving the life of people living with HIV Aids and the community 
at large ( Marconi V, 2014).  
 
4.2 The effect of switch to FDC for non -treatment naïve patients on 
adherence 
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Results from this study suggested that patients that were previously on MDC then switched to 
FDC demonstrated better proportion of days covered and absolute adherence ( at 12 and 24 
months) than those patients that were treatment naïve on FDC. The level of adherence for this 
group was almost constant over time, indicating low decline from 6 months to 24 months. 
Armstrong in 2015 also demonstrated the benefit of switching non-naïve patients to fixed dose 
regimens. However since the regimen switched to was the same as FDC regimen there must be 
other factors contributing to better performance. These reasons for switch according to the SA 
ART guidelines were for changing patients that were previously on known toxic regimens, for an 
example Stavudine based, and for reducing pill load for patients who were virally suppressed. 
These patients were already experienced on more complex regimens. At 6 months this study could 
not find significant differences in absolute adherence between those on MDC unswitched (64.7%) 
and FDC (65.5%), meaning these clients were already having similar levels of adherence early on 
in treatment, but being provided with even a simpler regimen would make them more capable of 
demonstrating even better adherence rates when a new simpler regimen was introduced. The 
motivation factor that wanes after 6 months, explained by the adherence curve theory would be 
applicable to FDC group, but not on those patients starting a new regimen. Motivational 
enhancement therapy as used in most addiction treatment regimens ( Holt, 2006),  works on the 
premise that access to treatment is never adequate ( Centre on addiction, 2017) but constant 
motivation and treatment support is needed for these patients that often relapse, that should be 
tailor made to address individuals needs including management of side effects. Enrolment of ART 
patients onto enhanced adherence clubs should be encouraged even for those patients not 
classified as defaulters. 
4.3 Impact of FDC on Viral Load suppression 
This study was able to demonstrate that even with less than optimum adherence levels, the 
Tenofovir/ emtricitabine/ efavirenz FDC regimen was able to achieve high viral load suppression 
rates up to 24 months. After 6 months the MDC switched group also demonstrated similar viral 
load suppression rates. The results indicate the positive benefits of using a fixed dose combination 
regimen on virologic response. Marconi, 2013 suggests that virologic response is an early warning 
indicator that can used to predict viral failure, and that it can be a measure of adherence. The study 
was able to confirm the positive strong correlation that exist between adherence and viral load 
suppression with FDC, significant at 0.01 level (2 tailed), however at 24 months this correlation 
was not significant. As VL suppression improved adherence was not improving proportionally. 
Therefore one can argue if viral load suppression can be used as an indicator of adherence for this 
regimen. Hingleyman (2016) proposes that taking the Tenofovir/ emtricitabine/ efavirenz FDC 
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regimen three times a week instead of daily can still maintain adequate VL suppression, but this 
is only applicable for patients already VL suppressed. This could have benefits of reducing the 
pill burden further. This study was able to demonstrate that patients with PDC below 50% were 
still able to achieve 93% VL suppression even at these low levels of adherence, in support of 
Hingleymans findings. However the study found that at 12 months, with these poor adherers VL 
suppression dropped to 56%. The practice of reducing the dosing frequency of FDC cannot be 
applicable to all patients, this could only be explored with only those clients with proven good 
adherence, above 95%, to reduce probability of side effects. In females the higher adherence 
levels achieved on FDC compared to males could not translate to better viral load suppression; 
negative correlation was found. Other factors other than adherence could contribute to this as 
proposed by Marconi (2013), such as ADRs, unsafe sex practices, depression that could be 
significant as contributing factors to viral failure.  
Resistance to antiviral therapy is the limiting factor in the management of patients with HIV. 
These viral mutations are more associated with low adherence to treatment. K65R mutation is 
rarely selected (1.7–4%) with tenofovir disoproxil fumarate (TDF) and abacavir (ABC), as 
compared with the high incidence (>40%) of thymidine analog mutations associated with 
zidovudine based regimens. TDF/emtricitabine and ABC/lamivudine (ABC/3TC) combinations 
are recommended due to the high barrier to the development of K65R mutations.  There is also 
low–intermediate level profile of cross-resistance conferred by K65R to TDF, ABC and 3TC.  
3TC/emtricitabine-associated M184V mutations.  The results have suggested that combination 
antiretroviral therapy (ART) have resulted in better maintenance of viral load suppression and led 
to marked decreases in mortality. The failure to suppress viral replication during therapy leads to 
the selection and expansion of drug-resistant viruses.   A study done by Brenner et al, in 2009, 
found similar results where there was high resistance to TDF based viral mutations in ART patient 
naïve patients.  
4.4 Impact of FDC on Immunologic response and death rates 
Cd4 count recovery was higher for MDC at 12 months, but the immunologic recovery was more 
sustained with FDC. Homar (2008) argues that by 24 weeks plasma viral load is suppressed to 
levels below 100 copies, but there is usually a delayed immune recovery, followed by a sustained 
increase over time. Cd4 count for FDC improved in spite of reduced adherence rates at 24 months. 
Cd4 count for MDC dropped at 24 months, and VL suppression also dropped to 56%. Cd4 count 
can be used to detect viral failure (Bisson, 2008) but this is not as accurate as using pharmacy 
records as measure of adherence (Marconi, 2013). Poor Immunologic response is correlated to 
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poor clinical outcomes (Castro, 2005). This was confirmed by higher death rates with MDC 
compared to FDC.   
4.5 General Conclusion 
This study was able to demonstrate that introduction of the fixed dose regimen was a good strategy 
to improve adherence levels, viral load suppression and immunologic response on ART. However 
the adherence levels were still lower than the optimal levels which might compromise care later 
on in treatment. The fixed dose combination regimen introduced was able to demonstrate good 
viral load suppression rates even in patients with 50% adherence at 6 months, indicating potency 
of the regimen. The study was only restricted to 24 months and no conclusive evidence could be 
demonstrated to show that as adherence reduced with time to levels below fifty percent, viral load 
suppression could still be maintained thereafter. What was evident from this study was that for 
those patients on FDC who had proportion of days covered on treatment less than fifty percent, 
beyond 6 months, viral load suppression almost halved, suggesting that additional strategies need 
to be adopted to further improve adherence. Switching of non-treatment naïve patients to FDC 
should be done more promptly. More adherence support needs to be provided to males to improve 
adherence. 
4.6 Recommendations for Future Research 
Future research should investigate the impact of side effects and adverse drug reactions of the 
tenofovir/ emtricitabine/ efavirenz based fixed dose regimen as a factor for non-adherence as this 
study identified a gap on the management of drug side effects and ADR’s. Further investigations 
need to be done on factors contributing to reduced viral load in females in spite of them having 
adherence rates than males. Further research needs to be conducted on the effectiveness of the 
FDC on viral load suppression when taken only three times a week as Hingleyman’s study 
proposes before 6 months and results of good suppression suggest from this study, as an 
alternative to managing side effects early on in ART treatment.  
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